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ABSTRACT

EFFECT OF NATURAL ANTIOXIDANTS ON MOTOR AND COGNITIVE DEFICITS IN
AN ANIMAL MODEL OF AGING AND OBESITY AND DOPAMINERGIC-LIKE SH-SY5Y
CELL LINE

By
Sneha Deepak Potdar
August 2018

Dissertation supervised by Jane E. Cavanaugh, Ph.D.
Aging is a universal phenomenon. One of the greatest challenges faced by the elderly population
is to sustain a healthy standard of living. Advancing age is associated with increased motor and
cognitive deficits. Loss of balance, falls, hip fractures, and poor memory all contribute to a
decline in the quality of life of the aging population. While ongoing research is making advances
to find therapeutic interventions for neurodegenerative disorders like Parkinson’s and
Alzheimer’s diseases, there is a pressing need to address deficits associated with normal aging.
Increase in oxidative stress and a decline of antioxidant mechanisms with aging have
been attributed to the incidence of deteriorated physical function, which is purported to
commence in middle age. Therefore, in this study, we explored natural antioxidants that may
have the potential to combat rising oxidative stress and weakening of physiological systems,
thereby improving motor and cognitive function of the older population. We supplemented the

iv

diet of middle-aged mice with resveratrol, a phytoalexin found in grapes, peanuts, wild blueberry
and red wine. Resveratrol is known for its antioxidant, anti-inflammatory, anti-cancer properties
and is also shown to be neuroprotective. During the course of our study, an unexpected
confounding factor in the form of weight gain was introduced. However, by controlling for the
increased bodyweight, we were able to evaluate resveratrol-mediated behavioral and molecular
changes in a novel over-eating induced obesity and aging model. Our results indicated that
prolonged resveratrol supplementation affected molecular changes in the brain, muscle and bone
that may be potentially be beneficial for combating obesity and aging related deficits.
In addition to resveratrol, we also tested its naturally occurring analog, piceid in an in vitro
model of oxidative-stress induced cell death in a dopaminergic-like cell line. Piceid afforded
neuroprotection against oxidative-stress induced toxicity via activation of ERK1/2 and ERK5
(extracellular signal-regulated kinases) as well as inhibition of cellular apoptosis.
In conclusion, our data suggest that natural antioxidants may combat physiological deficits
induced by obesity and aging and maybe potential therapeutic interventions for improving the
quality of life of the elderly.

v

DEDICATION

First and foremost I would like to express my heartfelt gratitude to my mentor Dr. Jane
Cavanaugh. Her professional and personal support has been instrumental in shaping my project.
She constantly encouraged me to hone my skills as a researcher, think outside the box and
persevere even if things are not going the way you intended them to. It has been an amazing
experience working under her tutelage, one that will always remain with me throughout my
career.
I would also like to sincerely thank my committee members, Dr. Matthew Kostek, Dr. Lauren
O’Donnell, Dr. Christopher Surratt and Dr. Zhengui Xia. Their time and scientific input for my
project has been invaluable. At a time when this project was suffering from major roadblocks,
they encouraged me to not give up but instead turn it around into a new and exciting direction.
For that and their support throughout my graduate career, I will always be extremely grateful.
I would also like to thank Dr. Matthew Kostek, Dr. Lauren O’Donnell and Dr. Paula WittEnderby for collaborating on this project, giving me an opportunity work with them and learn a
little about the muscle, spleen and bone. To Dr. Jelena Janjic, who introduced me to the
formulation lab and whose door was always open for a scientific discussion or a casual chat, I
will miss you immensely. I also want to thank Juliann Jaumotte and Sandra Scheirer from Dr.
Michael Zigmond’s lab at the University of Pittsburgh for their help with HPLC, Ly Li and
Maddie Omstead from Dr. Matthew Kostek’s lab for their help with muscle work and Dr.
Siddhartha Ray for his help and inputs on my work and manuscripts.
I have been fortunate to work with amazing colleagues: Dr. Erika Allen, Dr. Darlene Monlish,
Dr. Mayur Parmar, Thomas Wright and Akshita Bhatt. I want to specially mention Thomas

vi

Wright whose support and friendship helped me not only navigate some very stressful times but
also made them enjoyable. I will miss our endless chats about the most random topics. I can try
but never express in words the love and support of Dr. Mayur Parmar who is like family to me.
Even after graduating from our lab, he was always there to help and support me. His dedication
and passion for science is an inspiration and this project would not have been what it is without
his constant encouragement and insight. To my friends, Negin Nouraei, Irenej Jeric and Janja
Mirtic, I will always cherish the time spent with you all at Duquesne.
I want to also thank my parents Deepak and Karuna Potdar and my sister Janhavi for their love
and encouragement throughout my career.
Last but not least, to my best friend, confidante and fiancé, Sahil Sangani, I couldn’t have done it
without your unwavering love, support and encouragement.

You believed in me when

sometimes I did not believe in myself and pushed me to be a better person each day. Thank you
for always being the one I could count on, during my best days but especially during the worst
ones.

vii

TABLE OF CONTENTS

LIST OF FIGURES .....................................................................................................................................................XI
LIST OF TABLES ..................................................................................................................................................... XII
CHAPTER ONE ........................................................................................................................................................... 1
INTRODUCTION AND RATIONALE.................................................................................................................... 1
AGING AND OXIDATIVE STRESS .................................................................................................................................................. 1
NATURAL ANTIOXIDANTS IN AGING, MOTOR FUNCTION AND COGNITION........................................................................... 3
RESVERATROL IN CLINICAL STUDIES ......................................................................................................................................... 3
DOPAMINERGIC SYSTEM AND MOTOR FUNCTION .................................................................................................................... 4
OBESITY AND DOPAMINERGIC SYSTEM ..................................................................................................................................... 9
OBESITY, AGING AND MUSCLE FUNCTION ................................................................................................................................. 9
BONE, OBESITY AND AGING ....................................................................................................................................................... 10
COGNITION, AGING AND OBESITY ............................................................................................................................................. 10
RATIONALE AND EXPERIMENTAL DESIGN .............................................................................................................................. 11
MATERIALS AND METHODS ............................................................................................................................ 14
ANIMALS ...................................................................................................................................................................................... 14
DIETARY SUPPLEMENTATION WITH RESVERATROL ............................................................................................................. 14
BEHAVIORAL ANALYSIS ............................................................................................................................................................. 14
CHALLENGE BEAM TEST (CBT) ............................................................................................................................................... 15
SPONTANEOUS ACTIVITY TEST (SAT) .................................................................................................................................... 15
NOVEL OBJECT AND PLACE RECOGNITION TEST .................................................................................................................... 15
TISSUE PROCESSING ................................................................................................................................................................... 17
MUSCLE ........................................................................................................................................................................................ 17
BRAIN ........................................................................................................................................................................................... 18
BONE ............................................................................................................................................................................................ 18
SAMPLE PREPARATION .............................................................................................................................................................. 19
WESTERN BLOT ANALYSIS ........................................................................................................................................................ 19
HPLC ANALYSIS.......................................................................................................................................................................... 22
STATISTICAL ANALYSIS .............................................................................................................................................................. 22
RESULTS ................................................................................................................................................................. 23
ANIMALS ON THE SOFT PELLET DIET (CONTROL AND RESVERATROL‐SUPPLEMENTED) SHOWED SIGNIFICANT
INCREASE IN BODY‐WEIGHT...................................................................................................................................................... 23
BEHAVIORAL TESTS ................................................................................................................................................. 26
MOTOR FUNCTION ...................................................................................................................................................................... 26
Challenge beam test.............................................................................................................................................................. 26
Spontaneous activity test ................................................................................................................................................... 28
MEMORY TESTS........................................................................................................................................................................... 30
Novel object recognition..................................................................................................................................................... 30
Novel place recognition ...................................................................................................................................................... 30
MOLECULAR CHANGES IN THE TISSUES .................................................................................................................................. 32
Striatum ................................................................................................................................................................................... 32
Resveratrol significantly increased phosphorylated/total tyrosine hydroxylase in the striatum ...... 32
Resveratrol supplementation increased dopamine and DOPAC levels in the striatum ........................... 34
Resveratrol did not significantly alter D1 or reduced D2 receptor levels in the striatum...................... 36

viii

Resveratrol did not significantly alter pERK1 or pERK2 levels in the striatum .......................................... 38
Prefrontal cortex ................................................................................................................................................................. 40
Resveratrol increased levels of pERK2 but not total ERK1/2 in prefrontal cortex of overweight mice
....................................................................................................................................................................................................... 40
Resveratrol did not increase reduced voltage‐dependent anion channel (VDAC) levels ........................ 42
in the prefrontal cortex of overweight mice............................................................................................................... 42
SIRT1 levels were not affected by obesity or resveratrol supplementation................................................. 42
Muscle strength and function ...................................................................................................................................... 44
Muscle dissection weights and mean muscle force ................................................................................................. 44
Molecular changes in the muscle ............................................................................................................................... 47
Resveratrol up regulated reduced levels of VDAC in overweight mice .......................................................... 47
Molecular changes in the bone .................................................................................................................................... 49
Resveratrol caused significant reduction in the levels of pERK5, and up regulation of GLUT4 and
PPARγ ......................................................................................................................................................................................... 49
Blood glucose levels .......................................................................................................................................................... 50
Resveratrol did not modulate increased blood glucose levels in overweight animals ............................ 51
DISCUSSION........................................................................................................................................................... 54
GAIN IN BODYWEIGHT AS A CONFOUNDING FACTOR ............................................................................................................ 54
MOTOR FUNCTION TESTS .......................................................................................................................................................... 56
COGNITION AND MEMORY TESTS ............................................................................................................................................. 57
BRAIN ........................................................................................................................................................................................... 58
Striatum ..................................................................................................................................................................................... 58
Prefrontal Cortex (PFC) ...................................................................................................................................................... 60
Muscle ........................................................................................................................................................................................ 62
Bone ............................................................................................................................................................................................ 63
COMPARISON WITH PREVIOUS STUDIES IN CAVANAUGH LAB ............................................................................................. 64
CONCLUSIONS AND FUTURE DIRECTIONS .................................................................................................. 66

CHAPTER TWO ........................................................................................................................................................67
INTRODUCTION AND RATIONALE................................................................................................................. 68
MATERIALS AND METHODS ............................................................................................................................ 71
CELL CULTURE ............................................................................................................................................................................ 71
DA TREATMENT ......................................................................................................................................................................... 71
PICEID TREATMENT ................................................................................................................................................................... 71
U0126 OR XMD8‐92 INHIBITOR TREATMENTS .................................................................................................................. 72
CELL VIABILITY ASSAYS ............................................................................................................................................................. 72
CASPASE‐GLO® 3/7 ACTIVITY ASSAY .................................................................................................................................... 72
CELL LYSIS COLLECTION FOR WESTERN BLOT ANALYSIS ..................................................................................................... 73
WESTERN BLOTTING ................................................................................................................................................................. 73
STATISTICAL ANALYSIS .............................................................................................................................................................. 74
RESULTS ................................................................................................................................................................. 75
PICEID ATTENUATED DA‐INDUCED CELL DEATH IN SH‐SY5Y CELLS .............................................................................. 75
PICEID ACTIVATES PRO‐SURVIVAL PROTEINS ERK1/2 AND ERK5 IN SH‐SY5Y CELLS .............................................. 78
INHIBITION OF THE ERK1/2 AND ERK5 PATHWAYS ATTENUATES PICEID‐MEDIATED NEUROPROTECTION IN SH‐
SY5Y CELLS ................................................................................................................................................................................. 80
PICEID ATTENUATES DA‐INDUCED OXIDATIVE STRESS IN SH‐SY5Y CELLS .................................................................... 82
PICEID ATTENUATES DA‐INDUCED CASPASE‐3/7 ACTIVITY AND INCREASES LEVELS OF THE ANTI‐APOPTOTIC
PROTEIN BCL‐2 IN SH‐SY5Y CELLS........................................................................................................................................ 84
DISCUSSION........................................................................................................................................................... 87

ix

CONCLUSION AND FUTURE DIRECTIONS .................................................................................................... 89

REFERENCES ............................................................................................................................................................90

x

LIST OF FIGURES
Figure 1. Dopaminergic pathways in the brain .................................................................................... 7
Figure 2. Dopamine synthesis, release, uptake, and metabolism ................................................. 8
Figure 3. Schematic of experimental design for long‐term dietary resveratrol
supplementation ................................................................................................................................... 13
Figure 4. Bodyweight changes between diet groups with increasing age ............................. 24
Figure 5. Overweight mice made significantly more errors on the challenge beam test than
non‐overweight mice but time taken to cross the beam was not significantly different
...................................................................................................................................................................... 27
Figure 6. Hind limb steps were significantly reduced with increasing age and weight gain
...................................................................................................................................................................... 29
Figure 7. Resveratrol diet improved novel object but not novel place recognition at 6
months following diet initiation ..................................................................................................... 31
Figure 8. Resveratrol significantly increased both phosphorylated and total tyrosine
hydroxylase in the striatum of overweight mice .................................................................... 33
Figure 9. Resveratrol increased dopamine and DOPAC levels in the striatum of overweight
mice............................................................................................................................................................. 35
Figure 10. D2 but not D1 receptors were significantly reduced in overweight control
animals ...................................................................................................................................................... 37
Figure 11. Weight gain or resveratrol treatment had no significant effect on phosphorylated
and total ERK1 and ERK2 in the striatum of overweight mice ......................................... 39
Figure 12. Resveratrol increased levels of phosphorylated ERK2 but not total ERK1/2 in the
prefrontal cortex of overweight mice .......................................................................................... 41
Figure 13. Effect of resveratrol dietary supplementation on SIRT1 and VDAC levels in the
prefrontal cortex ................................................................................................................................... 43
Figure 14. Weight gain significantly reduced mean muscle force normalized to bodyweight
...................................................................................................................................................................... 45
Figure 15. Wet muscle weight did not differ between control and treatment groups ..... 46
Figure 16. Effect of resveratrol dietary supplementation on VDAC and PGC1α levels in the
gastrocnemius muscle ........................................................................................................................ 48
Figure 17. Effect of resveratrol dietary supplementation on molecular markers of bone
health ......................................................................................................................................................... 50
Figure 18. Blood glucose levels were significantly elevated in overweight mice .............. 52
Figure 19. Schematic of proposed changes due to weight gain and resveratrol
supplementation in the brain, bone and skeletal muscle.................................................... 53
Figure 20. Chemical structures of piceid and resveratrol............................................................. 76
Figure 21. Piceid (RV8) protects against DA‐induced toxicity in SH‐SY5Y cells ................. 77
Figure 22. Piceid (RV8) causes activation (phosphorylation) of ERK1/2 and ERK5 in SH‐
SY5Y cells ................................................................................................................................................. 79
Figure 23.Inhibition of ERK1/2 and ERK5 activation independently in SH‐SY5Y cells
attenuates RV8‐mediated neuroprotection .............................................................................. 81
Figure 24. Piceid attenuated oxidative stress associated with DA‐ induced toxicity ....... 83
Figure 25. Piceid (RV8) pretreatment attenuates DA‐mediated apoptosis in SH‐SY5Y cells
...................................................................................................................................................................... 85
Figure 26. Schematic of proposed neuroprotective mechanism of piceid ............................ 86
xi

LIST OF TABLES
Table 1. List of antibodies used in Chapter 1 ..................................................................................... 21
Table 2. Average food intake of mice on soft and hard pellet diet ............................................ 25

xii

CHAPTER ONE
INTRODUCTION AND RATIONALE
The number of people aged 65 and more in the Unites States is projected to reach about 80
million by 2050 1. One of the challenges faced by the elderly is to maintain a healthy lifestyle
and a good quality of life. Increasing age leaves the population susceptible to neurodegenerative
disorders such as Parkinson’s

2-4

and Alzheimer’s

5-7

. Additionally, with normal aging there is a

decline of motor co-ordination accompanied by a concurrent rise in incidences of falls, loss of
balance, fractures and augmented pain
cognition

13-15

8-12

. Aging is also associated with impaired memory and

. As a result, substantial healthcare costs are associated with the elderly. Health

care cost per capita for people older than 65 is about 3-5 times in the Unites States and other
developed nations compared to persons <65 years

16

. Depressive symptoms are associated with

decrease in physical health and quality of life 17-19.
Most therapeutic interventions are developed for neurodegenerative disorders. However, it is
important to address declining physical health with increasing age in order to afford a better
quality of life to the elderly population. Our study was aimed towards identifying potential
therapeutic/prophylactic targets for age-related motor and cognitive deficits.
Aging and oxidative stress
The free radical theory of aging postulates that damage to cellular components and
macromolecules is induced by highly reactive free radicals or reactive oxygen species, atoms or
groups of atoms with an unpaired electron [hydroxyl radical (ꞏOH), superoxide anion (O2 −),
hydrogen peroxide (H2O2)]. Aging renders the antioxidant defenses in the body less effective in
counteracting the reactive oxygen species, thereby damaging critical cellular components
including proteins, DNA and lipids

20-22

. Aerobic respiration involving molecular oxygen and

1

catalyzed by oxidative enzymes and trace metals are the most likely source of reactive oxygen
species

22

. This theory was supported by the discovery of superoxide dismutase in 1969, an

enzyme solely dedicated to removal of superoxide anions

23

. As majority of the reactions

involving molecular oxygen occur in the mitochondria, the electron transport chain (ETC) in the
mitochondria is the source of majority of the reactive oxygen species 20, 24-25. Electrons that leak
from the ETC can react with oxygen to produce free radicals

26-27

. The cell has antioxidant

defenses such as enzymes including thioredoxin peroxidase, catalase and glutathione peroxidase
28-29

to combat free radicals and prevent cellular damage. However, these defenses decline with

increasing age 30. Mitochondrial function and amount of mitochondrial DNA are also known to
tissue-specifically decline with increasing age

31-33

leaving tissues vulnerable to mitochondrial

dysfunction.
Aging, oxidative stress, motor function and cognition
Age-related oxidative stress is implicated in loss of motor co-ordination and cognitive abilities.
A study by 34 examined the relationship between oxidative damage in the brain, motor skills and
cognitive function in old (22 month) mice. They found that with increasing oxidative stress in the
brain, motor and cognitive abilities declined. There was no co-relation between the degrees of
cognitive and motor impairments indicating that the dysfunctions resulted from damage to
separate regions of the brain. In a study by 35, motor and cognitive loss was seen to manifest in
middle and old age. This is an important finding as including only young and old age groups
makes it difficult to discern fine changes that may have an onset in the middle age (40-50 years
in humans). Previously,

36

observed motor function deficits beginning to occur in 12-month-old

middle-aged mice. Therefore, our rationale in this study was to start therapeutic intervention in
middle age to possibly attenuate or prevent the onset of motor and cognitive deficits.

2

Natural antioxidants in aging, motor function and cognition
Naturally occurring polyphenols are widely used as food and medicines

37-38

. Over 10,000

polyphenols possessing different bioactivities have been identified in fruits, vegetables, teas and
medicinal plants

39-42

. They are touted for their health benefits in age-related disorders, cancer,

cardiovascular diseases and especially antioxidant potential

43-44

. Studies have found a diet rich

in polyphenols to improve cognitive and sensorimotor functions in aging mice 45.
Studies by our lab and others

35-36

have established the importance of a middle-aged group in

aging studies. Resveratrol (3, 4’, 5-trihydroxystilbene), a natural phytoalexin, is found in
peanuts, grapes, wild blueberries and red wine. It is synthesized de novo as an antimicrobial and
antioxidant defense in plants in response to stress, injury, U.V. radiation or attack by pathogens
46-47

. Resveratrol has shown promise in many in vitro and in vivo studies. In cancer models,

resveratrol prevented DNA binding of (NF)-Κβ, a transcription factor that is up regulated and
drives tumor proliferation of cancer cells, reduced tumor cell proliferation by inhibiting
cyclooxygenase and promoted tumor cell apoptosis by promoting cell cycle arrest

48-50

. Studies

have also shown resveratrol’s beneficial effects against inflammation 51 and its role in extending
lifespan of multiple organisms 52.
Resveratrol in clinical studies
Resveratrol has been tested for its therapeutic potential in several clinical trials, primarily for
cancer, neurological disorders, diabetes and obesity and cardiovascular diseases 53. Consumption
of 0.5 to 1.0g of resveratrol per day for 8 days was found to reduce colorectal tumor proliferation
in twenty patients

54

. A 12-week administration of 0.5-5mg twice-daily reduced methylation of

the tumor suppressor gene RASSF-1α in thirty-nine women at increased breast cancer risk

55

.

Resveratrol administration for 1 month at a 5mg dose twice-daily decreased insulin resistance,

3

blood glucose levels and oxidative stress in Type 2 diabetes patients56. Although resveratrol has
not been studied with respect to motor function in clinical trials, long-term administration (12
month) has shown beneficial effects in Alzheimer’s disease including attenuated decline in Aβ42
and Aβ40 and reduced matrix metallopeptidase-9 in the cerebrospinal fluid

57-58

. These studies

indicated the potential beneficial effects of resveratrol in physiological deficits with increasing
age.
We therefore chose to test resveratrol, for chronic dietary supplementation starting at middle age,
to evaluate effects of long-term oral resveratrol administration on motor and cognitive deficits in
an aging animal model. The precise molecular mechanisms of resveratrol’s effects are still being
evaluated. However, resveratrol is a known activator of sirtuins, a class of proteins that are
deacetylases or mono-ADP-ribosyltransferases

59-62

. Resveratrol specifically activates sirtuin1

(SIRT1), which deacetylates peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC1α) that then promotes mitochondrial biogenesis

63-64

. These effects may provide

potential benefits in tissues such as skeletal muscle that require a high mitochondrial number and
function. Resveratrol is also known to activate extracellular signal-regulated kinases 1/2
(ERK1/2). ERK1/2 is a signaling cascade responsive to oxidative stress and while research is
conflicting, some groups have found activation of ERK1/2 to be protective against oxidative
stress65-67. Our study intended to assess if resveratrol supplementation affected any of these
pathways in our model.
Dopaminergic system and motor function
Basal ganglia, cerebellum and cerebral cortex are involved in maintaining motor co-ordination 6869

. Dopamine, a catecholamine, is an important neurotransmitter that regulates multiple functions

including movement and motor learning 70-74. Primarily, four main dopaminergic pathways have

4

been identified in the brain: the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular 75
(Figure 1). Dopamine is synthesized from the non-essential amino acid, tyrosine, which is taken
up via a transporter into the dopaminergic neurons. Dopamine synthesis occurs in two steps.
First, tyrosine is converted to L-3, 4 dihydroxyphenlyalanine (L-DOPA). The enzyme tyrosine
hydroxylase (TH) is essential and the rate-limiting enzyme in this step. TH needs to be
phosphorylated for the tyrosine to L-DOPA reaction to occur. Dopamine synthesis is therefore
closely modulated by TH activity. L-DOPA is then converted to dopamine by aromatic amino
decarboxylase (AADC).

Dopamine is transported for storage to vesicles by the vesicular

monoamine transporter 2 (VMAT2). Substantia nigra pars compacta (SNpc) and the ventral
tegmental area (VTA) house the majority of dopamine cell bodies in the dopaminergic system
76

. Dopamine neurons from the SNpc project to the dorsal striatum, which forms the nigrostriatal

pathway. The nigrostriatal pathway is important for control of voluntary movement

77

.

Dopamine is released into the synaptic cleft following an action potential at the axon terminal by
fusion of the synaptic vesicles with the plasma membrane. The released dopamine then binds to
G-protein coupled dopamine receptors that are divided in two main subtypes; D1 and D2. D1 and
D5 belong to the D1 receptor subtype while D2, D3 and D4 are included in the D2 subtype.
Their classification is based on their coupling and modulation of adenylyl cyclase

75, 78

. D1

subtype of receptors activates cyclic AMP (cAMP) dependent protein kinases via stimulation of
Gαs/olf and adenylyl cyclase

79-80

while D2 subtype couple to Gαi/o and inhibit adenylyl cyclase

activity 81-83.
Following its release, dopamine is rapidly taken up by dopamine transporters (DAT) that are
present on the presynaptic terminals. This uptake maintains auto regulation of dopamine
synthesis by increasing or decreasing the TH-mediated enzymatic reaction, in response to

5

dopamine levels. Dopamine is also metabolized in the dopaminergic neurons. Monoamine
oxidase

(MAO-A)

and

aldehyde

dehydrogenase

convert

dopamine

into

3,4-

dihydroxyphenylacetic acid (DOPAC). DOPAC is then converted to homovanillic acid (HVA)
by catechol-O-methlytransferase (COMT). Dopamine can also be converted to 3methoxytyramine (3-MT) by COMT that is then converted to HVA by MAO-B and aldehyde
dehydrogenase (Figure 2). The levels of these metabolites are therefore important indicators of
the functioning of the dopaminergic system. Decline of striatal dopamine and dopamine receptor
levels are considered to be factors influencing declining motor co-ordination with age 84-90.

6

Figure 1. Dopaminergic pathways in the brain
DLPFC-Dorsolateral prefrontal cortex; VMPFC-Ventromedial prefrontal cortex
Adapted from “Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical
Applications, 4th Ed.Chapter 4. Psychosis and schizophrenia
https://doctorlib.info/pharmacology/stahls-essential-psychopharmacology-4/4.html

7

Figure 2. Dopamine synthesis, release, uptake, and metabolism
TH-Tyrosine hyroxylase; AADC-aromatic amino acid decarboxylase; L-DOPA-L-3, 4dihydroxyphenylalanine; DA- dopamine; DAT- dopamine transporter;
MAO - monoamine oxidase; COMT-catechol-O-methyltransferase; DOPAC - 3, 4dihydroxyphenylacetic acid; HVA- homovanillic acid; 3-MT-3-methoxytyramine ; D1/D2Dopamine receptors (1/2); DβH-Dopamine beta hydroxylase; PNMT- Phenylethanolamine Nmethyltransferase; AC-Adenyly cyclase; cMAP: Cyclic adenosine monophosphate
Adapted from 91
8

Obesity and dopaminergic system
Dopaminergic system is involved in reward circuit of the brain. Intake of addictive substances
such as cocaine causes dopamine to be released in the reward center of the brain (mesolimbic
center including nucleus accumbens) and reinforces addictive behavior 92. Obesity is associated
with lower levels of striatal dopamine and dopamine receptors, especially D2
postulated to lead to binge-eating to stimulate dopamine production

96-97

93-95

which is

. We therefore

hypothesized that we would observe a similar eating behavior in our study in order for the
animals to reach increased reward thresholds. As resveratrol has shown beneficial effects in
aging and obesity, our goal was to probe its effects in our model using behavioral motor function
tests and analysis of components of the dopaminergic system.
Obesity, aging and muscle function
In addition to neuronal control of motor function, muscle health plays an important role in
maintenance of sensorimotor co-ordination. Sarcopenia, a loss of muscle strength and function
with increasing age, exacerbates loss of balance, falls and fractures in older adults

98-99

. Obesity

adds another dimension to sarcopenia, leading to a condition known as sarcopenic obesity where
age-related increase in bodyweight is accompanied by loss of muscle strength and function
102

. In a study by

103

100-

, sarcopenic obesity was shown to compound difficulties in physical

function. Sarcopenic obesity is an important contributor to reduced mobility in older population
104-106

. Currently physical activity, aerobic and resistance training are the primary treatment

options explored for sarcopenic obesity
muscle strength and function

107-108

102, 104

. As resveratrol has shown beneficial effects on

, we aimed to address whether it may also be a potential

therapeutic intervention for sarcopenic obesity in our model.
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Bone, obesity and aging
Osteoporosis or low bone mass is a concern for about half the population over the age of 50
years and osteoporotic fractures occur in men as well although women are primarily afflicted by
this condition

109-110

. Growing evidence supports the role of obesity in deteriorating bone health

as excess weight alters cell metabolism in bone and increases oxidative stress, thereby leaving
obese population vulnerable to bone fractures and possibly increased mortality and morbidity 111114

. Previous studies have explored favorable effects of resveratrol on bone health including

stimulation of proliferation and differentiation of cells secreting bone matrix (osteoblasts) and
inhibition of osteoclasts, the bone resorption cells

115-117

. In our study we focused on molecular

markers of bone health including ERK1/2 and Runx2; regulators of terminal chondrocyte
differentiation, (NF)-Κβ; an inflammatory and stress response molecule
postulated to be involved in bone remodeling

120-121

118-119

and ERK5;

. Additionally, the study also intended to

evaluate the role of obesity and resveratrol on PPARγ, a nuclear transcription factor involved in
regulation of bone metabolism and mass 122 and Glucose Transporter 4 (GLUT4), which plays a
critical role in insulin-dependent glucose uptake in mature osteoblasts 123.
Cognition, aging and obesity
Normal aging is associated with a decline in cognitive abilities

124

. Loss of cognition in the

elderly leads to difficulty in performing day-to-day tasks. Memory and attention are some of the
most affected aspects along with processing speed and reasoning

124-125

. Evidence from

126-127

suggests that weight gain with increasing age has a negative co-relation with multiple aspects of
cognitive function including attention, verbal memory and speed of processing. For the purposes
of this study, we will focus on working and spatial memory for representing cognitive defects.
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Working memory is a complex construct that promotes retaining information for a short period
of time for later access and manipulation. Both visual and auditory forms of information are
assimilated as working memory

128

. In a study by

129

older adults (age range: 66–79 years)

performed significantly worse compared to young adults (age range: 22–34 years) on working
memory task.

Working memory decline is thought to begin around middle age

prefrontal cortex (PFC) is known to support working memory

131-132

130

. The

. Aging weakens the ability

of PFC to maintain persistent firing of neurons 133 while increased bodyweight is correlated with
deficits in working memory

134

. In our study, working memory was measured using the novel

object recognition test. It is a non-aversive test that substitutes a novel object in place of a
familiar one and the time spent exploring the novel object is indicative of the animal’s preference
for novelty and retention memory 135-136. The test does not require external reward or motivation
and instead relies on the natural exploratory behavior of mice 136.
Spatial memory is part of the cognitive system that records navigational information, and uses it
to find a way through one’s environment 137. Studies by 138-141 have observed that spatial memory
declines with advancing age and increase in bodyweight. To test spatial memory in our model,
we used the novel place recognition test. Similar to novel object recognition, the animals were
habituated with familiar objects and tested by placing one of them in a different location. Time
spent exploring the familiar object in a novel place was used as an index to measure spatial
memory in our model.
Rationale and experimental design
In a previous study from our lab 36 observed the onset of motor function deficits in middle-aged
animals. Sarcopenia, dementia and osteopenia are also known to afflict the middle-aged
population. Our study was therefore designed to initiate dietary supplementation with resveratrol

11

(120mg/kg of food; consistent with the previous study in our lab) in middle-aged male C57BL/6
mice (13-15 months), a strain commonly used for aging studies. Obesity in the aging population
is known to increase the risk for type 2 diabetes and cardiovascular dysfunction. In order to
elucidate molecular and behavioral effects of resveratrol in a model of aging and obesity, our
study consisted of three groups. 1] Control (Non-overweight) 2] Control (Overweight) 3]
Resveratrol-supplemented (Overweight). Originally the study was designed to conclude after 10
months, when mice reached old age (23-25 months). However due to weight gain, there was
some attrition in the treatment groups that was attributed to increased risk of the cardiovascular
system by the consulting veterinarian. We therefore concluded the study at 8 months. Animals
were allowed ad libitum access to food, which was weighed every 3-4 days to calculate an
approximate dose of resveratrol per animal per day. The bodyweight was also recorded every 3-4
days. Behavioral tests for motor and cognitive function were performed at 2-month intervals. In
the study by

36

, behavioral tests were conducted at 1-month intervals, however the dietary

supplementation was short-term (2 months). For our long-term study, a 2-month interval was
established to avoid fatigue induced by repeated testing. At the conclusion of the study, ex vivo
muscle function tests were performed following which animals were sacrificed. Multiple tissues
including brain, bone, spleen, muscle, heart, kidney, liver and lungs were harvested for
molecular analysis.
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Experimental Design

Resveratrol
(120 mg/kg of food)

Motor func on
and cogni ve func on
tests (2 month intervals)
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Day of
sacrifice
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Sacrifice

Analyze for molecular
changes
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4

Figure 3. Schematic of experimental design for long-term dietary resveratrol
supplementation
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MATERIALS AND METHODS
Animals
Middle-aged (13-15 month) old C57BL/6 male mice (Jackson Laboratories, Farmington,
Connecticut) were housed (4 per cage) in the Animal Care Facility (ACF) at Duquesne
University. The animals had ad libitum access to water and food and were maintained on a 12 h
light: dark cycle. The study was in compliance with the Guide for the Use and Care of
Laboratory Animals, The Institutional Animal Care and Use Committee guidelines and all
regulations as applicable by the National Institutes of Health.
Dietary supplementation with resveratrol
Animals had ad libitum access to a specially formulated diet supplemented with resveratrol
(120mg/kg) for 32 weeks. The diet (TD.10738) was custom made in small batches at Harlan
Teklad laboratories (Madison, WI) to by adding resveratrol (TCI America, R0071) to standard
rodent diet (Purina rodent chow). Owing to the softer texture of TD.10738 compared to regular
purina chow found in the ACF at Duquesne University, a control diet (TD.92708) that is
similarly manufactured and possess comparable texture to TD.10738, was also incorporated in
the study.
Behavioral analysis
A total of three behavioral tests were performed. Baseline tests were carried out at the beginning
of the study followed by behavioral tests at 2, 4 and 6 months after the start of dietary
supplementation.
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Challenge beam test (CBT)
To test fine motor co-ordination, we used the challenge beam test to measure various parameters
of motor function. These included total number of errors and time taken to cross the beam. CBT
was developed by (Fleming et al. 2004) after modifying traditional challenge beam tests. The
test consists of a Plexiglas beam (25 cm by 3.5 cm at the widest end) divided in four segments
that get progressively narrower (0.5 cm at the narrowest end in 1 cm increments). The home cage
of the animal to be tested is placed at the narrowest end, as motivation to traverse the beam. The
animals are trained to cross the beam on two consecutive days for five trials each. On the third
(test) day, a fine wire mesh (1 cm2 openings) is placed on the beam that allows for detection of
fine sensorimotor deficits. Animals undergo five test trials, are videotaped and scored by an
investigator blinded to the treatment.
Spontaneous activity test (SAT)
Animals were videotaped for 3 min in a clear Plexiglas cylinder (15.5 cm X 12.7 cm) placed on
an elevated platform (6 inches). A mirror was placed underneath the cylinder facing the
videotape to visualize the steps taken by the mice. The parameters measured were forelimb and
hind limb steps, time spent grooming and rears. One rear was counted when the mouse lifted and
placed both the front paws on the vertical glass wall and then returned to the floor. A step was
counted when both the paws moved across the floor. Grooming was defined as the time spent by
the animal was sitting and moved its forepaws across its face, ears or muzzle.
Novel object and place recognition test
Place and object recognition tests were performed over 6 consecutive days and consisted of three
primary phases: acclimatization to the field (Day 1 and 2; 10 min per animal), exposure to
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familiar objects (Day 3 and 4; 5 min per animal), novel object recognition (Day 5; test day; 5
min per animal) and novel place recognition (Day 6; test day; 5 min per animal).
1) Acclimatization
The animals were placed on a smooth green polyvinylchloride plastic surface (45 cm × 60
cm × 60cm) surrounded by a black box to prevent escape from the field arena. Animals were
placed in the field for 10 min to get acclimatized.
2) Familiarization
On an identical surface as used in the acclimatization phase, two brackets were fixed to hold
identical stimulus objects (saline bottles, light bulbs, mugs) on the opposite corners of the
field. Animals were not able to displace or hide under the objects. Two dim diffuse lamps
were used to minimize shadows from the objects. 24 hours following the second day of
acclimatization, the animals were placed in the arena for 5 min to get familiar with the
objects followed by the same process after 24 hours.
3.1) Novel object recognition
24 hours following Day 4 (Day 2 of familiarization), the animals were placed in

the

arena, where a novel object replaced one familiar object. The time spent by the animal
exploring (counted when the head of the animal was 4 cm or closer to the object) was
videotaped by an overhead JVC video camera. Objects were cleaned with 70% isopropanol
between trials.
3.2) Novel place recognition
24 hours following the novel object test, animals were tested for their spatial
memory using the novel place recognition test. Objects from the familiarization
phase were used, however, one of the objects was located in a different position
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(towards the center of the arena as opposed to the corners). Animals were
videotaped and the same criteria as novel object recognition were applied to
measure exploration. Both sets of videos were analyzed by an investigator
blinded to the treatment.
3.3) Exploration ratio
For both the tests, exploration ratio was calculated by dividing the time spent
by the animal exploring novel object/place by the total time spent by the animal
exploring both the objects. Animals that spent a total of less than 10 sec
exploring objects were excluded from the final analysis.
Tissue processing
Animals were sacrificed by decapitation at the end of 32 weeks. The following tissues were
harvested.
Muscle
Following the last day of dietary supplementation, muscle function tests were performed prior to
decapitation. The animals were anesthetized using isoflurane and sciatic nerve from the right leg
was exposed. It was placed over two bipolar silver electrodes and stimulated by a continuous 4volt square-wave pulse lasting 0.1 ms. Muscle length in which maximal tension is obtained
during a single twitch (Lo) was used for measurement. Maximum isometric tension (Po) (Po;
stimulation frequency of 75-150 Hz) was recorded in grams, normalized to weight and used for
further data analysis. Time to fatigue and time to peak tension under constant stimulation were
quantified. Once the muscle test measurements were complete, skeletal muscles from the hind
limb (gastrocnemius, EDL, TA and soleus) were dissected, weighed, snap frozen in isopentane
cooled in liquid nitrogen and stored at -800C. Ex-vivo analysis included western blot, H&E
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staining and immunohistochemistry. 12 μm sections, from the mid-belly of gastrocnemius, were
cut using a cryostat, stained with H&E and observed using Olympus BX41, Infinity Analyze
version 4.4, 400X magnification (15 random fields per mouse). All muscle analysis was
performed in collaboration with Dr. Matthew Kostek’s laboratory, Rangos School of Health
Sciences, Duquesne University.
Brain
Following decapitation, the brain was harvested, rinsed with sterile saline solution and placed in
a mouse brain block. Prefrontal cortex, hippocampus, striatum and hindbrain were dissected.
Prefrontal cortex, hippocampus and striatum were rapidly frozen on dry ice and stored at -800C.
Hindbrain was fixed in 4% formaldehyde/4% NaF in phosphate buffer for 48 hours and then
stored at 40C in 30% sucrose in 1X PBS.
Bone
Tibia from the left and right leg was harvested, cleaned off muscle tissue and stored as required
for further analysis. The left tibia was snap frozen in liquid nitrogen and stored at -800C. The
right tibia was fixed in 4% formaldehyde/4% NaF in phosphate buffer for 48 hours and then
stored at 40C in 30% sucrose in 1X PBS. For western blot analysis, the left tibia was pulverized
mechanically under liquid nitrogen using a ceramic mortar and pestle. The pulverized sample
was collected into a 6 mL plastic tube containing a 2 mL solution (2% sodium dodecyl sulfate,
2M urea, 10% glycerol, 10 mM Tris-HCl(pH 6.8), 10 mM dithiothreitol, and 1 mM
phenylmethylsulfonylfluoride). A TissueTearerTM was used to homogenize the suspension on ice
in 10-15 sec of bursts. The solution was kept on ice for 30 min to allow particulate matter to
settle, centrifuged at 15,000 rpm and the supernatant collected. The lysate was mixed with 2X
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Laemmli buffer in a 1:1 ration and stored at -200C for further analysis. Bone analysis was
performed in Dr. Paula Witt-Enderby’s lab with assistance from Ryan Ryland.
Sample preparation
Tissue (brain and muscle) was homogenized in 1X RIPA (Cell Signaling Technology, Danvers,
MA) buffer on ice (20L /mg of tissue) using a probe sonicator. The sample was then spun down
(40C; 10,000 rpm) and the supernatant was used for western blot analysis.
Western blot analysis
60g protein, as determined by Bradford protein assay, was run on a SDS-PAGE gel (8-12% as
per the protein size) at 100V for 2 hours. The gels were transferred to a nitrocellulose membrane
(Li-Cor Biosciences; Lincoln, NE). 5 mL of Casein blocking buffer (Li-Cor Biosciences;
Lincoln, NE) was used to block the membranes for 1 hour at room temperature. The membranes
were probed with respective antibodies (listed in Table 1). Following washes (3X for 10 min
with 1XPBS+ 0.2% Tween), the membranes were incubated with secondary antibody (1: 10,000,
Li-COR Biosciences) for 1-2 hours. Blots were scanned using an Odyssey Imager and Li-COR
Image Studio lite software was used for quantification and analysis. Background subtraction was
performed using the left and right pixelated area of the bands. Quantification was performed
using gray scale images.
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Primary antibodies
Antibody
phospho tyrosine hydroxylase
(pTH)
total tyrosine hydroxylase (t
TH)
Dopamine receptor 1 (D1)

Type and dilution
(Product code) and company
rabbit anti phospho TH(Ser31) (3370), Cell Signaling, USA
(1:1000)
rabbit anti total TH (1:1000)
(2792), Cell Signaling, USA
rabbit anti-Dopamine D2
Receptor (1:1000)
rabbit anti-Dopamine D2
Receptor (1:500)
Rabbit anti-SIRT1 (1:1000)
Rabbit anti-VDAC
(D73D12)mAb (1:1000)
Rabbit anti-PGC-1, CTerminal (777-797)
(1:1000)

(324390), Millipore Sigma,
USA
(AB5084P), Millipore Sigma,
USA
(2310), Cell Signaling, USA
(4661) Cell Signaling, USA

phospho extracellular signal
regulated kinase1/2
(pERK1/2)
total extracellular signal
regulated kinase1/2
(pERK1/2)
phospho extracellular signal
regulated kinase 5(pERK5)

rabbit anti-phospho ERK1/2
(1:1000)

(9101), Cell Signaling, USA

mouse anti-total ERK1/2
(1:1000)

(9107), Cell Signaling, USA

rabbit anti-phospho
ERK5(1:500)

(3371), Cell Signaling, USA

Glucose transporter 4

rabbit anti-GLUT4 (1:1000)

Runt-related transcription
factor 2 (RUNX2)
NF-κB (nuclear factor kappalight-chain-enhancer of
activated B cells)
β-actin
Glyceraldehyde 3-phosphate
dehydrogenase

goat anti-RUNX2 C-19
( 1:1000)
rabbit anti-NFκB(1:1000)

(sc7938), Santa Cruz Biotech,
USA
(sc-8566), Santa Cruz
Biotech, USA
(sc298), Santa Cruz Biotech,
USA

Dopamine receptor 1 (D2)
Sirtuin1 (SIRT1)
Voltage dependent anion
channel (VDAC)
Peroxisome proliferatoractivated receptor gamma
coactivator 1-alpha (PGC-1α)

mouse anti-β-actin (1:20,000)
mouse anti –GAPDH
(1:10,000)

(516557), Millipore Sigma,
USA

(926-42212), Licor, USA
(CB1001), Millipore, Sigma,
USA

Secondary antibodies
Antibody and Type

Dilution
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(Product code) and
company

goat anti-rabbit (IRDye
680LT)
goat anti-mouse (IRDye
800CW)
Donkey anti-goat
(IRDye800CW)

1:20,000
1:20,000
1:20,000

Table 1. List of antibodies used in Chapter 1
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(926-68021), Licor
Biosciences, USA
(926-32210), Licor
Biosciences, USA
(926-32214), Licor
Biosciences, USA

HPLC analysis
HPLC was performed (Dr. Michael Zigmond’s lab, University of Pittsburgh) to determine the
levels of dopamine and its metabolites (HVA, DOPAC) as well as the neurotransmitter 5hydroxytrptamine (5-HT) and its metabolite 5-hydroxyindolacetic acid (5-HIAA) in the striatum
of control and resveratrol fed animals. Samples were weighed and homogenized (20μL of 0.1N
PCA per mg of sample). A 20μL aliquot was analyzed by HPLC as described in Allen et al.,
2017. The mobile phase (75 mM H2NaPO4, 1.7 mM octanesulfonic acid, 25 mM Na2EDTA
0.00001% triethylamine (v/v), and 10% acetonitrile (v/v), pH 3.0) was pumped through the
system at a rate of 0.3 mL/min. The column was ESA C18 column (2.1×150 mm, ESA, Inc.,
Chelmsford, MA). An ESA Coulochem Model 4100A detector, an ESA Model 5010
conditioning cell, and an ESA Model 5014B micro dialysis cell (ESA Inc., Chelmsford, MA)
were used to detect the sample coulorimetrically. All samples were run in duplicates and
quantified based on a series of standards with linear correlations of > 0.99997 for each
compound (4 sets composed of 3 concentrations starting at the beginning of the run and after
every 8th sample).
Statistical analysis
All statistical analysis was performed using SPSS V25. As the increase in bodyweight was a
confounding factor, data was analyzed using ANCOVA, a modification of ANOVA that corrects
for the confounding factor post experimental execution. Data was analyzed using a one-way or
two-way ANCOVA with the appropriate post hoc correction as noted in respective figures. Data
in (Figure 5C) was analyzed using one-way ANOVA followed by Dunnett’s post hoc correction.
Statistical significance was defined at p<0.05.
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RESULTS
Animals on the soft pellet diet (control and resveratrol-supplemented) showed significant
increase in body-weight
The study was initiated with two groups of animals: control and resveratrol-supplemented.
However, after about 4-5 weeks, we noticed a significant increase in bodyweight of the animals
on the soft-pellet resveratrol supplemented food. As the resveratrol diet was custom made and
differed in texture and compactness from the control diet in the ACF, we added a third group of
mice to the study. They received a diet similar in texture and consistency to the resveratrol diet.
As shown in (Figure 4), animals on the specially formulated soft pellet diet gained a significant
amount of weight over the duration of the study. Weight of animals on the control and
resveratrol soft pellet diet started significantly differing at Week 4 and Week 9 respectively from
control animals on hard pellet diet and remained significantly higher at Week 32. This is not
indicated in (Figure 4) to avoid cluster of significance signs. The food intake was higher for both
the control and resveratrol fed overweight mice compared to control non-overweight mice (Table
2) by about 2-2.2 gram/day. The percent increase in bodyweight did not significantly differ
between the soft-pellet groups, indicating that increased food intake, not the resveratrol
supplementation, contributed to the augmented bodyweight (Figure 4B).
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Figure 4. Bodyweight changes between diet groups with increasing age
Results are presented as + SEM. Bodyweight (grams) was measured every 3 days. (A) Mice fed
the soft pellet diet gained significant bodyweight compared to their counterparts on the hard
pellet. Resveratrol diet as hard pellet was not available in this study. (B) Percent increase in
bodyweight compared to Week 1. Data was analyzed using two-way ANCOVA followed by post
hoc analysis using an uncorrected Fisher’s LSD test.
Weight of animals on the control and resveratrol soft pellet started significantly differing at
Week 4 and Week 9 respectively from control animals on hard pellet diet and remained
significantly higher at Week 32. This is not indicated in the figure to avoid cluster of significance
signs.
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Table 2. Average food intake of mice on soft and hard pellet diet
Results are presented as + SEM. Food intake (grams) was measured every 3 days. Resveratrol
diet as hard pellet was not available in this study. n=9-17
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Behavioral tests
Motor function
In this study, two types of behavioral tests were used to measure motor function deficits:
Challenge beam and Spontaneous activity tests.
Challenge beam test
The test was performed according to the procedure described in Materials and Methods. Placing
the fine wire mesh allows measurement of fine sensorimotor co-ordination. Owing to the
significant bodyweight increase, mice were unable to navigate the 4th segment of the beam.
Therefore, this segment was excluded from our analysis when data for all three groups was
compiled. (Figure 5C) shows the errors for only the non-overweight control mice and includes
errors from Segment 4. Overweight control and resveratrol supplemented animals made
significantly more errors compared to their age-matched non-overweight counterparts (Figure
5A). Time taken to cross the beam was not significantly different between treatment groups
(Figure 5B). In addition to the total number of errors, other parameters including 1) errors per
trial (Figure 5D-F) on segment 1-3 and 2) errors per segment (Figure 5G-I) at each 2-month
interval were also assessed with no significant difference between the groups.
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Figure 5. Overweight mice made significantly more errors on the challenge beam test than
non-overweight mice but time taken to cross the beam was not significantly different
Total errors made at start of the study (baseline), 2 months, 4 months, 6 months after diet
initiation on (A) Segment 1-3 (B) Time take to cross the at start of the study (baseline), 2
months, 4 months, 6months (C) Errors made by non-overweight mice on the entire challenge
beam (Segment 1-4) Time to cross per trial at (D) 2 months, (E) 4 months, (F) 6 months, Errors
per segment at (G) 2 months, (H) 4 months, (I) 6 months. Data are presented as + SEM and
analyzed using two-way ANCOVA followed by post hoc analysis using an uncorrected Fisher’s
LSD test (n=8-10). (Figure 5C) Data are presented as + SEM and analyzed using one-way
ANOVA followed by Dunnett’s post hoc correction.
# indicates compared to non-overweight age matched mice. (# p<0.05, ## p<0.01)
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Spontaneous activity test
Exploratory behavior and activity were examined using the spontaneous activity test as described
in Methods section. Animals were videotaped for 3 min in a Plexiglas cylinder and the tapes
scored by an investigator blinded to the treatment. Four parameters were analyzed 1) Number of
rears 2) Forelimb steps 3) Hind limb steps 4) Grooming time (Figure 6).
There was no significant difference in number of rears, forelimb steps or grooming time between
control and treatment times (Figure 6A, Figure 6B, Figure 6D). The number of hind limb steps
was significantly lower in the overweight control and treatment groups compared to baseline
(diet-matched) as well as their age-matched non-overweight counterparts (Figure 6C).
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Figure 6. Hind limb steps were significantly reduced with increasing age and weight gain
Spontaneous activity at start of the study (baseline), 2 months, 4 months, 6 months after diet
initiation as measured by (A) number of rears (B) number of forelimb steps (C) number of hind
limb steps (D) time spent grooming. Data are presented as + SEM and analyzed using two-way
ANCOVA followed by post hoc analysis using an uncorrected Fisher’s LSD test (n=8-10).
# indicates compared to non-overweight age matched mice. (# p<0.05, ## p<0.01, # p<0.001)
∞indicates compared to diet matched mice at baseline. (∞ p<0.05, ∞∞p<0.01, ∞∞∞ p<0.001)
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Memory tests
Novel object recognition
To test if obesity with increasing age and resveratrol supplementation had an effect on working
memory, animals were tested according to the novel object recognition paradigm. According to
(Figure 7A), overweight mice spent significantly less time exploring the novel object compared
to non-overweight mice while resveratrol-fed animals explored the novel object for a
significantly longer duration compared to overweight control mice. The data indicated that
resveratrol supplementation improved working memory in overweight mice.
Novel place recognition
Similar to novel object recognition, the novel place recognition test was performed to assess
spatial memory of the animals. As seen in (Figure 7B), there is no significant difference in the
exploration ratio of over-weight control mice compared to non-overweight control animals.
Resveratrol supplementation did not appear to affect the time spent exploring the object located
in a novel place.
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Figure 7. Resveratrol diet improved novel object but not novel place recognition at 6
months following diet initiation
Exploration ratio plotted at start of study (baseline), 2 months, 4 months, 6 months for (A) Novel
Object recognition test (B) Novel Place recognition test
Data are presented as + SEM and analyzed using two-way ANCOVA followed by post hoc
analysis using an uncorrected Fisher’s LSD test (n=8-10).
# indicates compared to age-matched non-overweight mice (## p<0.01)
* indicates compared to age-matched overweight mice on control diet (** p<0.01)
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Molecular changes in the tissues
Although we did not observe changes in the behavioral tests, we examined probable molecular
changes due to resveratrol supplementation in multiple different tissues.
Striatum
Resveratrol significantly increased phosphorylated/total tyrosine hydroxylase in the
striatum
Tyrosine hydroxylase is an important enzyme for dopamine synthesis, which catalyzes the ratelimiting step of converting tyrosine to L-DOPA.

Tyrosine hydroxylase needs to be in its

phosphorylated form for the reaction to occur. The levels of total and phospho tyrosine
hydroxylase in the striatum were significantly reduced in the overweight control mice compared
to the non-overweight control animals. Interestingly, resveratrol supplementation restored the
levels of both phospho and total tyrosine hydroxylase in the treatment group as compared to the
overweight control animals (Figure 8).
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Figure 8. Resveratrol significantly increased both phosphorylated and total tyrosine
hydroxylase in the striatum of overweight mice
Levels of (A, B) phosphorylated tyrosine hydroxylase and (C) total tyrosine hydroxylase were
significantly reduced in overweight control mice. (D) Representative image for Figure 8(A-C).
Resveratrol diet significantly increased striatal phosphorylated and total tyrosine hydroxylase in
overweight mice. Data are presented as + SEM and analyzed using one-way ANCOVA followed
by post hoc analysis using Bonferroni’s test (n=5-7).
# indicates compared to non-overweight mice (# p<0.05)
* indicates compared to overweight mice on control diet (* p<0.05)
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Resveratrol supplementation increased dopamine and DOPAC levels in the striatum
The catecholamine dopamine plays a role in modulation of motor function control. As dopamine
is converted to DOPAC and HVA, measurement of DOPAC and HVA levels is an indicator of
the amount of dopamine synthesized. The levels of neurotransmitter dopamine and its metabolite
DOPAC were significantly reduced in overweight control animals, indicating that obesity affects
the dopaminergic system. Resveratrol supplementation reversed this decline of neurotransmitter
levels in the striatum. Increase in DOPAC levels was statistically significant while increase in
dopamine levels showed a trend towards significance (p=0.053). Levels of 5-HT and its
metabolite 5-HIAA were unchanged by obesity or dietary supplementation in the striatum
(Figure 9).
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Figure 9. Resveratrol increased dopamine and DOPAC levels in the striatum of overweight
mice
Levels (μM) of (A) Dopamine and (B) DOPAC were significantly reduced in overweight control
mice. Resveratrol diet significantly increased dopamine (p=0.053) and DOPAC levels in
overweight mice (C) HVA (D) 5-HT and (E) 5-HIAA were not changed with increasing weight.
Data are presented as + SEM and analyzed using one-way ANCOVA followed by post hoc
analysis using Bonferroni’s test (n=5-7).
# indicates compared to non-overweight mice (# p<0.05)
* indicates compared to overweight mice on control diet (* p<0.05)
p=0.053 compared to overweight mice on control diet
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Resveratrol did not significantly alter D1 or reduced D2 receptor levels in the striatum
Dopamine is the primary ligand for dopamine receptors and they are involved in fine motor
control, learning and cognition. Levels of the two receptors, D1 and D2, were probed by western
blot in the striatum. There was no significant change in the D1 receptor levels however there was
a significant reduction in D2 receptor levels in overweight mice. Resveratrol treatment was not
able to reverse this reduction of D2 receptors in the striatum (Figure 10).
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Figure 10. D2 but not D1 receptors were significantly reduced in overweight control
animals
Levels of (A) D1 receptors and (B) D2 receptors in the striatum. D2 receptors were significantly
reduced in overweight control mice. Resveratrol did not affect D1 or D2 levels in the striatum.
(C) Representative image for Figure 10A and 10B. Data are presented as + SEM and analyzed
using one-way ANCOVA followed by post hoc analysis using Bonferroni’s test (n=5-7).
# indicates compared to non-overweight mice (# p<0.05)
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Resveratrol did not significantly alter pERK1 or pERK2 levels in the striatum
ERK1/2 is involved in neuronal protection against oxidative stress. Levels of phosphorylated
ERK1 and ERK2 were unchanged in the striatum of overweight aged mice in both control and
treatment groups (Figure 11). Total ERK1 and ERK2 did not significantly differ in the three
groups. These data indicate that in the striatum, weight gain and resveratrol supplementation do
not have an effect on the levels of ERK1/2.
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Figure 11. Weight gain or resveratrol treatment had no significant effect on
phosphorylated and total ERK1 and ERK2 in the striatum of overweight mice
No significant change was observed in levels of (A) phosphorylated ERK1 (B) phosphorylated
ERK2 and (C) total ERK1 (D) total ERK2 in overweight control or treated mice. (E)
Representative image for Figure 11 (A-D). Data are presented as + SEM and analyzed using oneway ANCOVA followed by post hoc analysis using Bonferroni’s test (n=5-7).

39

Prefrontal cortex
Resveratrol increased levels of pERK2 but not total ERK1/2 in prefrontal cortex of
overweight mice
ERK1/2 is involved in neuronal protection against oxidative stress. As the prefrontal cortex is
involved in memory regulation, changes in ERK1/2 were analyzed by western blot. Levels of
pERK2 but not pERK1 were significantly lower in overweight control mice compared to nonoverweight control mice. Resveratrol supplementation increased pERK2 levels compared to the
overweight control mice. There was no change in total ERK1 or ERK2 protein (Figure 12).
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Figure 12. Resveratrol increased levels of phosphorylated ERK2 but not total ERK1/2 in
the prefrontal cortex of overweight mice
Levels of (A) phosphorylated ERK1 (C) total ERK1 and (D) total ERK2 were not changed with
increased weight or resveratrol supplementation. (B) phosphorylated ERK2 was significantly
reduced in overweight control mice and this attenuation was reversed in the resveratrol treated
overweight group. (E) Representative image for Figure 12 (A-D). Data are presented as + SEM
and analyzed using one-way ANCOVA followed by post hoc analysis using Bonferroni’s test
(n=5-7).
# indicates compared to non-overweight mice (# p<0.05)
* indicates compared to overweight mice on control diet (* p<0.05)
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SIRT1 levels were not affected by obesity or resveratrol supplementation
Surprisingly SIRT1, a signaling pathway known to be modulated by resveratrol, and which is
involved in improving mitochondrial metabolism and glucose homeostasis, was not significantly
different between the three groups in the prefrontal cortex (Figure 13A).
Resveratrol did not increase reduced voltage-dependent anion channel (VDAC) levels in
the prefrontal cortex of overweight mice
Mitochondrial protein VDAC controls cross talk between mitochondria and the rest of the cell by
functioning as a gatekeeper for the entry and exit of mitochondrial metabolites and is also a key
player in mitochondria-mediated apoptosis. Levels of VDAC, in the striatum of overweight mice
were significantly reduced compared to their lean counterparts. Resveratrol treatment was not
able to reverse the loss of VDAC levels in the prefrontal cortex (Figure 13B).
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Figure 13. Effect of resveratrol dietary supplementation on SIRT1 and VDAC levels in the
prefrontal cortex
(A) SIRT1 levels in the prefrontal cortex were not affected by weight or resveratrol treatment.
(B) VDAC levels were significantly reduced in overweight mice. Resveratrol supplementation
did not affect the reduced VDAC levels in overweight animals. (C) Representative image for
Figure 13A and 13B. Data are presented as + SEM and analyzed using one-way ANCOVA
followed by post hoc analysis using Bonferroni’s test (n=5-7).
# indicates compared to non-overweight mice (# p<0.05)
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Muscle strength and function
Muscle strength is an important contributor to motor function. Skeletal muscle function tests
were performed as described in Materials and Methods.
Muscle dissection weights and mean muscle force
Skeletal muscles consist of primarily two types of fibers; slow and fast twitch. Slow twitch fibers
are involved in building endurance while fast twitch fibers have a greater impact on daily
activities that require a relatively quick force production such as climbing stairs or catching
oneself from a fall. Soleus consists of primarily slow twitch fibers while tibialis anterior and
extensor digitorum longus are mostly made up of fast twitch fibers. The gastrocnemius is a
mixed muscle and consists of both slow and fast twitch fibers. Analysis of these muscles would
give a comprehensive picture of changes in muscle fiber types and their contribution to any
differences in muscle strength tests performed on the hind limb. These muscles also primary
contributors to movements of the hind limb and their analysis will contribute to teasing apart
structural and histological changes between the three groups in the study.
Muscle force, normalized to bodyweight, was significantly reduced in overweight animals. These
data indicate that muscle function maybe compromised, as the skeletal muscles may not be able
to support the excess bodyweight. Resveratrol supplementation did not have an effect on the
reduced muscle force of overweight mice (Figure 14).
There was no difference in the weight wet of hind limb skeletal muscles between the treatment
and the control groups (Figure 15).

44

A

B

Control (Non‐overweight)
Control (Overweight)
Resveratrol (Overweight)

Figure 14. Weight gain significantly reduced mean muscle force normalized to bodyweight
(A) Mean muscle force raw values (B) Mean muscle force normalized to bodyweight.
Overweight mice had significantly reduced mean muscle force/kg of bodyweight. Resveratrol
supplementation did not have an effect on the muscle force of overweight animals. Data are
presented as + SEM and analyzed using one-way ANCOVA followed by post hoc analysis using
Bonferroni’s test (n=5-7).
# indicates compared to non-overweight mice (## p<0.01)
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Figure 15. Wet muscle weight did not differ between control and treatment groups
Muscle dissection weights of hind limb skeletal muscles: right and left gastrocnemius, right and
left soleus, left tibialis anterior, left extensor digitorum longus. Data are presented as + SEM
(n=9-11)
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Molecular changes in the muscle
Left gastrocnemius was analyzed using western blot to test the effects of obesity, aging and
resveratrol supplementation on markers of oxidative stress and mitochondrial function.
Resveratrol up regulated reduced levels of VDAC in overweight mice
VDAC levels were significantly reduced in overweight mice compared to their non-overweight
counterparts. Increased VDAC levels in the resveratrol group showed a trend towards
significance compared to overweight control animals (Figure 16A).
PGC1 in the gastrocnemius muscle was not affected by obesity or resveratrol treatment
PGC1α is a downstream target of SIRT1 and similarly involved in mitochondrial metabolism.
Increase in weight and resveratrol treatment did not cause any significant change in PGC1α
levels in the gastrocnemius muscle (Figure 16B).
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Figure 16. Effect of resveratrol dietary supplementation on VDAC and PGC1α levels in the
gastrocnemius muscle
(A) Resveratrol supplementation increased reduced VDAC levels (p=0.066) in overweight mice.
(B) PGC1α levels in the gastrocnemius muscle were not significantly affected by weight or
resveratrol treatment. (C) Representative image for Figure 16A and 16B. Data are presented as +
SEM and analyzed using one-way ANCOVA followed by post hoc analysis using Bonferroni’s
test (n=5-7).
# indicates compared to non-overweight mice (# p<0.05)
p=0.066 compared to overweight mice on control diet
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Molecular changes in the bone
Left tibia of the mice in all three groups was used for western blot analysis.
Resveratrol caused significant reduction in the levels of pERK5, and up regulation of
GLUT4 and PPARγ
Proteins important to the bone strength and function were probed in the left tibia using western
blot. ERK1/2, ERK5 and Runx-2 are involved in regulation of osteoblast and osteoclast
differentiation while NFKβ is an inflammatory molecule that is also important for
osteoclastogenesis. GLUT-4 and PPARγ are mediators of insulin and glucose homeostasis in the
bone. Resveratrol did not significantly affect levels of pERK1/2, NFKβ or Runx-2 although
levels of NFKβ and Runx-2 were significantly lower in both the overweight groups compared to
the non-overweight animals (Figure 17 B, C, D). Interestingly, resveratrol up-regulated the
significantly low levels of GLUT4 and PPARγ in the overweight mice (Figure 17 E, F). Contrary
to GLUT-4 and PPARγ, pERK5 was significantly higher in overweight control animals. This
increase was attenuated by resveratrol (Figure 17A).
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Figure 17. Effect of resveratrol dietary supplementation on molecular markers of bone
health
(A) Resveratrol significantly attenuated the increased pERK5 levels in overweight animals. (B)
pERK1/2 was not significantly affected by weight gain or resveratrol diet. (C) (NF)-Κβ and (D)
Runx-2 were significantly reduced in the overweight control and treated groups. (E) PPARγ and
(F) GLUT4 levels were decreased in overweight control animals. Resveratrol supplementation
increased levels of both (E) PPARγ and (F) GLUT4 in overweight mice. (G) Representative
image for Figures 17(A-F). Data are presented as + SEM and analyzed using one-way ANCOVA
followed by post hoc analysis using Bonferroni’s test (n=7-9).
# indicates compared to non-overweight mice (# p<0.05, ## p<0.01)
* indicates compared to overweight mice on control diet (* p<0.05, ** p<0.01, ** p<0.001)
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Blood glucose levels
Resveratrol did not modulate increased blood glucose levels in overweight animals
Blood glucose levels were measured using a Freestyle Freedom monitor to assess if resveratrol
had an effect on increased glucose levels attributed to weight gain. Due to the timing of sacrifice
required for muscle analysis, the measurements were taken just before the animals were
decapitated. Ideally, the assessment would be more accurate if taken at the same time with both
pre and postprandial readings. Owing to these limitations, the readings are not conclusive.
However, on a preliminary basis, resveratrol did not appear to modulate blood glucose levels
(Figure 18).
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Figure 18. Blood glucose levels were significantly elevated in overweight mice
Resveratrol supplementation did not affect significantly increased blood glucose levels in
overweight mice. Data are presented as + SEM and analyzed using one-way ANCOVA followed
by post hoc analysis using Bonferroni’s test (n=9-17).
# indicates compared to non-overweight mice (## p<0.01)
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DISCUSSION
Gain in bodyweight as a confounding factor
The gain in bodyweight was a result of an unexpected confounding factor. Mice on the
resveratrol diet started gaining bodyweight around Week 4 (Figure 4). The resveratrol diet was
specially formulated at Harlan Teklad laboratories by incorporating resveratrol powder in mouse
purina chow that was used as the control diet. The caloric value of both the diets is similar with
the comparable percentage of calories derived from protein, fats and carbohydrates. The diets
differed in texture and hardness; the pellets of resveratrol diet were much softer and crumbled to
powder easily. No instrumental analysis was used to distinguish these differences; they were
based on manual inspection only. The reason for this difference was the custom manufacture of
resveratrol diet without external heat application, on smaller machines and using less compaction
force as compared to traditional purina chow. Food was provided ad libitum and weighed every
third day to determine the total amount of resveratrol ingested by the animals. During the course
of the study, we observed that animals on resveratrol diet ate around 2 grams/day more than
those on control purina chow. One hypothesis was that resveratrol was causing an increase in the
bodyweight however available literature on resveratrol did not support this conclusion 142-143. An
alternative explanation was increase in the amount of food eaten per day could be a contributing
factor to the weight gain. To address this question, we included a third group of animals on a diet
similar in texture and hardness of pellet to resveratrol diet but excluding the active ingredient.
Due to technical and funding limitations, we could only acquire one additional set of animals and
commence dietary supplementation after completion of the first study (control mice on hard
pellet and resveratrol treated mice on the soft pellet). Possibly due to acquiring animals at a
different time, the third set of animals, although belonging to the same species, came from a
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different cohort and started at a lower bodyweight than the first two (Figure 1A). To address this
issue, increase in percent bodyweight was calculated; the percentage was very similar in the two
groups on the soft pellet diet (Figure 1B) over 32 weeks. Originally, our study was aimed at
evaluating motor and cognitive deficits in an aging model. However, due to the increased
bodyweight, an additional facet of obesity was introduced. Diet based obesity studies have
generally used a high fat diet 144-145. Compared to around 26-27% of calories obtained from fats
from the diet in our study, high fat diets generally are formulated to provide around 60% of the
total calories from fatty ingredients like lard, beef tallow or coconut oil 146-147. Though these diets
induce obesity in rats and mice quickly for a rapid screening of compounds, a diet supplying
60% calories from fats would probably represent an extreme case in humans. Obesity in humans,
in general, results from increased eating and a decline in physical activity

148

. In our model,

weight gain was affected by an increase in food intake rather than a formulated high fat diet.
Thus our model may provide a good representation of obesity induced due to overeating.
Resveratrol has shown beneficial effects in obesity models using a high-fat diet

149-150

. To the

best of our knowledge, our study is the first to probe the effects of resveratrol in an aging and
overeating-induced obesity model.
Previously our lab found that oral resveratrol administration for 2 months showed improvement
in motor function deficits in old mice

36

. To test whether dietary supplementation starting at

middle age halts the onset of motor and cognitive deficits, mice were fed a diet supplemented
with resveratrol at around 13-15 months of age. As the treatment group started unexpectedly
gaining weight, a third group on a control diet, similar in texture and pellet hardness to the
resveratrol diet was added to the study. To the best of our knowledge, these data are the first to
probe changes due to simply over-eating of food without addition of any high fats/sugar. These
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data are important as with an increasing sedentary lifestyle, the incidence of obesity is on the
rise. Obesity, especially in older adults is co-related with a decline in motor and cognitive
function

151

. Not only are overweight individuals prone to health issues including hypertension,

diabetes, heart disorders,
individuals
157

153

152

they also have lower life expectancy compared to non-overweight

. Obesity is associated with poor cognition

154-155

and motor function deficits

156-

with increasing age.

Obesity studies, for the most part, use high-fat diets to induce excess weight gain

158-159

. While

the differences between overeating of normal food vs. a high fat diet were beyond the scope of
this study, the results from these experiments elucidated behavioral and molecular changes
induced by excessive eating in aging mice. This study could be used as a preliminary model for
how overeating of regular food induces changes in the body that may, in part, be similar to eating
a high-fat diet.
Motor function tests
To study the motor function deficits, the challenge beam test was used, as it is an indicator of
fine motor co-ordination 160. However, due to the excessive weight gain, the animals were unable
to correctly traverse the narrowest segment (4th) of the beam, especially towards the end of the
study. They often dragged themselves across the segment, thereby rendering the analysis of
motor function deficits on this part of the beam inconclusive. Nevertheless, analysis of the first
three segments showed that overweight mice made significantly more errors than the nonoverweight animals and resveratrol treatment did not affect these errors. There was no significant
difference in the time taken to cross the beam. This parameter is measured as the time taken to
walk only when the animal is taking a forward step and excludes any amount of time that the
animal is stationary and/or grooming on the beam.
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Although the overweight control and

resveratrol treated mice had difficulty walking across due to their weight, the total time as
measured by forward steps did not significantly differ from the non-overweight animals.
It is possible that resveratrol did not improve motor function in this model; however, the dose of
resveratrol (120mg/kg of food) used in this study was decided based on 36, where the study was
not confounded by overeating induced weight gain. It is possible that a higher dose would be
necessary to effect a behavioral change. Additionally, a test that is not affected by weight (gait
walking) may offer a better measure of motor function in our model.
There was no significant alteration in the parameters measured for the spontaneous activity test
(rears, number of forelimb steps and grooming time). These data indicate that aging, obesity and
resveratrol treatment did not affect the exploratory activity of the animals (as measured by rears).
This was a surprising observation as the rears are mediated, in part, by dopamine
neurotransmission

161-163

. Levels of dopamine were low in overweight control group. Possibly,

the excess weight mediated another signaling pathway or the animals were motivated to explore
for food due to their increased appetite. The number of hind limb steps was significantly reduced
in the overweight animals. As the excess weight was concentrated around the mid-section of the
mice, it may be the contributing factor to the animals’ lethargic hind limb movements.
Cognition and memory tests
Novel object and place recognition tests were performed to assess learning and memory in our
animal model. Aging and obesity are both risk factors for memory loss 164-167. One of the aims of
this study was to test if resveratrol supplementation improves cognitive loss associated with
obesity and aging. We found that working memory as measured by novel object recognition was
impaired in overweight control animals. However, the test paradigm followed resulted in a
caveat. As seen in (Figure 7A), the exploration ratio for the overweight mice was less than 50%,
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indicating that the mice spent more time exploring the familiar object. If the mice had truly
impaired memory, they would be spending an equal amount of time exploring both familiar and
novel objects, as they would not remember the introduction of the novel object of a different
shape on the test day. More time exploring the familiar object indicates that they could prefer the
shape of the familiar object more than that of the novel object and hence does not give us a true
indication of the state of working memory in these animals. The novel place recognition is a
better indicator of memory, as it involves the same objects and therefore no bias is introduced
towards a different shape.
We did not observe a significant difference in the spatial memory function as measured by novel
place recognition following resveratrol diet. One conclusion is that resveratrol did not affect
spatial memory in these animals. However, the design of the test was such that the spatial
memory was tested 48 hours following the familiarization phase. Although, animals were
familiarized for two consecutive days, 48 hours is a long time for retention of spatial placement
of the objects. A more robust paradigm would be to test the mice within a few hours of the
familiarization phase. The results from such a study design would offer more conclusive data
regarding memory loss and the effect of resveratrol on cognition in our model.
In spite of not observing significant behavioral changes, different regions of the brain, muscle
and bone were probed to detect molecular changes caused by overeating and resveratrol dietary
supplementation.
Brain
Striatum
As motor function with aging was one of the primary aims of this study, levels of phosphorylated
and total tyrosine hydroxylase were measured. Tyrosine hydroxylase, part of the dopaminergic
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system, is an important enzyme in the dopamine synthesis pathway. Interestingly, both phospho
and total tyrosine hydroxylase levels were significantly reduced in aged overweight mice. These
results agree with studies by 168, where tyrosine hydroxylase mRNA expression was significantly
reduced in the dopaminergic region of high-fat diet fed C57Bl/6 mice and findings of

169

showing reduced TH+ immunoreactivity in the substantia nigra of high-fat diet fed mice.
Although we were not able to analyze the errors on all the segments of the challenge beam test
and therefore conclusively determine motor function deficits, increased bodyweight has been
shown to correspond to decreased motor co-ordination and increased injuries due to falls and
balance problems.

169-170

. Even discounting the fourth segment, overweight mice made

significantly more errors on the first three segments of the beam than non-overweight mice.
Studies have shown that food and drugs (such as cocaine) exert their rewarding properties party
by activation of the mesolimbic system

93

. Chronic drug abuse or excessive food consumption

may cause overstimulation of the dopamine receptors and can result in their down regulation. D1
receptors are recycled and can return to the cell surface to bind ligands while D2 receptors are
degraded by G protein coupled receptor-associated sorting protein (GASP) in the lysosomes
172

171-

. The difference in the mechanism of action of D1 and D2 receptor endocytosis could serve as

one possible explanation for the data seen in this study.
Resveratrol treatment did not affect the reduced striatal D2 receptor levels. Dopamine levels in
the whole tissue were increased in the treatment group although they did not reach statistical
significance; the p value was very close to 0.05 (p=0.066). These data indicate that resveratrol
could be modulating dopamine levels, possibly by increasing the levels and activity of tyrosine
hydroxylase. In this study, resveratrol did not appear to affect dopamine receptor levels. Levels
of serotonin (5-HT) and its metabolite 5-Hydroxyindoleacetic acid (5-HIAA) were also
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measured in the control and treatment group. Interestingly, there was no change in striatal 5-HT
and 5-HIAA. This is contrary to previous studies that have found higher levels of 5-HT in lean
groups of dogs 173 as well as induction of hyperphagia and obesity in rats with depleted serotonin
174

. It is possible that in C57BL/6 mice, dopamine modulation affects weight and appetite to a

greater extent than serotonin.
175-176

Levels of phospho and total ERK1/2 were also measured in the striatum. Studies by

have

shown that H2O2 mediated activation of ERK1/2 plays a critical role in cell survival rat PC12
cells and primary cortical neurons against oxidative stress. In addition, considering the weight
gain in our model, probing ERK1/2 in the brain was significant as the hormone inhibiting
hunger, leptin, has been shown to activate ERK pathway

177-178

. In this model, we hypothesized

that due to over-eating, the leptin regulation was likely impeded and therefore ERK activation
would be reduced in the overweight animals. However, there was no significant difference in the
levels of phospho and total ERK between the three groups. Leptin is also known to modulate
other signaling pathways AMPK, PI3K, mTOR, STAT3, STAT5

177

which could possibly be

involved and future studies could probe for their regulation in this model.
Prefrontal Cortex (PFC)
In addition to the striatum we also probed the PFC for different markers including ERK1/2,
VDAC and SIRT1, the signaling pathway known to be activated by resveratrol

64, 179

. There are

mixed reports on the effect of resveratrol on ERK1/2 activation; in prostrate and renal carcinoma
cells resveratrol has been shown to inhibit ERK1/2
ERK1/2 in a model of chronically stressed rats
unpredictable mild stress
induces depression

184

183

182

180-181

while it has been shown to activate

, in rats facing cognition impairment due to

and in mice subjected to forced swim and tail suspension test that

. In our model, to further narrow down the signaling mechanisms, we
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looked at ERK1 and ERK2 separately. Interestingly, while there was no significant change in
levels of pERK1, pERK2 was reduced in overweight animals. Resveratrol fed animals showed a
significant increase in levels of only pERK2 while total protein remained constant across all
groups. These data indicate that ERK1 and ERK2 are differently regulated and possibly perform
varying roles. While these disparities were not further explored in this dissertation, investigation
of differing ERK1 and ERK2 roles in future experiments will provide a greater insight in the
function of these proteins. We were unable to probe for ERK5, another member of the MAPK
family that is also known to play a neuroprotective role (Cavanaugh 2004), in the striatum, PFC
and muscle as the anti-ERK5 (Table 1) antibody was undetectable in these lysates.
We also probed for SIRT1 levels in the prefrontal cortex. Not only is resveratrol a well-known
SIRT1 regulator but SIRT1 is down regulated by a high-fat diet

185-188

and its levels decrease

with increasing age187-189. Surprisingly, there was no significant difference between SIRT1 levels
in all three groups although SIRT1 in non-overweight mice was slightly higher. Given the
available literature on resveratrol’s modulation of SIRT1 190-192, we expected to observe a change
in SIRT1 levels at least in the overweight resveratrol group. One possible reason for these
observations is that SIRT1 activation by resveratrol may require additional factors. A study by
193

showed that lamin A is important for SIRT1 activation by resveratrol. We can speculate that

due to obesity and increasing age, some critical factors for SIRT1 activation maybe missing or
present in amounts low enough to not support SIRT1 activation. A more exhaustive study
including investigative analysis of such factors may provide a viable explanation for our
observed data.
In addition to signaling pathways, we also probed for proteins involved in the mitochondrial
function. Mitochondrial dysfunction is a hallmark of the aging brain 194-197. Additionally, obesity
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has also been shown to impair mitochondrial function 198-199. We probed for VDAC in the brain
and gastrocnemius muscle (discussed in the next section). The trends for both the tissues were
similar; VDAC was low in overweight mice and the levels increased in the treatment group.
Muscle
A rise in oxidative stress levels with increasing age damages skeletal muscle 200-201, contributing
to motor function deficits. In our study, in addition to evaluating changes in the brain, we also
investigated functional and molecular changes in the skeletal muscle. There was no significant
difference in the wet weight of any of the muscles (gastrocnemius, TA, EDL, soleus). This was
a surprising observation as we expected some atrophy of muscles to be associated with the
increased bodyweight on account of decreased activity (less hind limb steps as seen in the
cylinder test). Previous studies

202-204

have observed that muscle weights are reduced in obese

mice compared to lean mice. However, our data indicated that the hind limb muscles might not
be able to support the increased bodyweight and as a result produce less overall muscle force.
This hypothesis was validated in the strength tests where muscle force was reduced in the
overweight groups, with resveratrol having no effect on this parameter. At the time of writing
this dissertation, further tests are underway in Dr. Matthew Kostek’s laboratory including muscle
fiber typing and measuring cross sectional area of individual muscle fibers to examine for any
abnormal shape or inflammation.
In addition to muscle strength tests, we also probed for changes at a molecular level; VDAC, a
measure of mitochondrial function, and PGC1/SIRT1 pathway that is known to be important
for resveratrol activity

179, 205

. VDAC was significantly reduced in the overweight control group

indicating that either mitochondrial number or function or both are possibly compromised with
excess weight gain. Our results agree with other studies showing mitochondrial dysfunction with
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obesity

206-209

. While resveratrol treatment did not significantly increase VDAC levels, the p

value trended towards significance (p=0.066). Future studies probing mitochondrial biogenesis
and other protein markers (cytochrome c) will provide further insights into resveratrol’s effect on
skeletal muscle bioenergetics.
Contrary to our hypothesis, we did not see a significant change in PGC1 levels in the
gastrocnemius. We also probed for SIRT1 but for an unknown reason, we were unable to
visualize this protein in gastrocnemius. However, levels do not indicate the functional state of
PGC1. SIRT1 deacetylates PGC1, which then regulates energy metabolism in skeletal muscle
63, 210-211

. Probing for deacetylated PGC1

210

will be a more reliable indicator of resveratrol’s

effect on this particular pathway.
Bone
Molecular markers were also probed in left tibia, as resveratrol is known to improve age-related
bone loss

212-213

as well as bone health in obesity

214-216

. We observed a significant reduction of

PPARγ levels and GLUT4 receptors in overweight control animals consistent with studies by 217218

. Resveratrol increased both PPARγ levels and GLUT4 receptors in the treatment group

indicating a potential hypoglycemic effect in the treatment group

219

. However, there was no

significant reduction in blood glucose levels in both the overweight groups. The measurements
were taken just before sacrificing the animals due to the design of the experiment. A more
controlled pre and postprandial blood glucose level would be a better measure however it is
possible that the increased glucose uptake (not specifically measured) was not enough to affect
the blood glucose levels. Taken together our results indicate that resveratrol diet exhibited
positive molecular changes in bone health of overweight mice. Interestingly, resveratrol inhibited
pERK5 that was significantly increased in the tibia of overweight mice. There exist conflicting
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reports of MEK5/ERK5 pathway in bone health. A study by

220

has shown MEK5 to inhibit

osteoblast differentiation, an important pathway for bone remodeling while

120

and

121

have

shown ERK5 to be important for osteoblast and osteoclast differentiation respectively. During
the course of our study, we collected the right tibia for further bone strength tests. The finding
from these studies will be pertinent to determine the role of MEK5/ERK5 in our model. We
found no difference in pERK1/2 while Runx-2 was significantly attenuated in both the
overweight groups indicating that an increase in bodyweight reduced the chondrocyte and
osteoblast differentiation, thereby possibly weakening bone strength 221. Resveratrol did not have
an effect on its levels. Surprisingly, (NF)-Κβ levels were reduced in the overweight groups. We
expected (NF)-Κβ to be reduced in the resveratrol group on account of its antioxidant and antiinflammatory properties but not in the overweight control group. Obesity has shown to be an
activator of the (NF)-Κβ 222-223. However, in the bone, (NF)-Κβ is also an important regulator of
osteoclast differentiation
osteoclasts

225

224

. Deletion of (NF)-Κβ resulted in a complete deficiency of

that can result in osteopetrosis, an abnormal hardening of bones

226

. A more

comprehensive analysis of upstream regulators of (NF)-Κβ including receptor activator of
nuclear factor kappa-Β (RANK) and its ligand (RANKL)

227

combined with results from bone

strength tests will provide a better understanding of the regulation of bone metabolism in our
model.
Comparison with previous studies in Cavanaugh lab
A previous study in our lab examined the effects of short-term (2 month) dietary
supplementation with natural antioxidants including resveratrol, its analogue (pinostilbene) and
wild blueberry on age-related motor functions. Both resveratrol and wild blueberry
supplementation attenuated motor function deficits (Allen, E., 2013, The effect of L-dopa and
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natural products on age-related motor deficits and dopaminergic cell survival, Duquesne
University, Pittsburgh, PA). Resveratrol activated neuroprotective pathways ERK1/2 in the
striatum but dopaminergic markers including dopamine, DOPAC and tyrosine hydroxylase were
unaltered. In our long-term study resveratrol did not show improvement in motor function
deficits following chronic administration, possibly due to the weight gain that resulted in a lower
dose per animals compared to the short term study. Chronic resveratrol supplementation also
increased levels of total and phosphorylated tyrosine hydroxylase, dopamine and DOPAC
attenuated by weight gain. These data indicate that long-term resveratrol diet maybe affecting
synthesis of tyrosine hydroxylase, which may then result in an increase in dopamine levels
(Figure 2). We did not observe activation of ERK1/2 in the striatum however attenuated pERK2
levels in the prefrontal cortex were significantly increased; further indicating that resveratrol
exerts differential effects depending on specific brain regions, duration of administration and
dose. We also observed changes in molecular markers of glucose homeostasis and cellular
differentiation in the bone that were not examined in the short-term study. Taken together, our
data indicates that chronic resveratrol dietary supplementation may affect modulation of the
dopaminergic system and a dose corrected for bodyweight may show improvement in motor
function decline similar to that observed in the short-term study.
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CONCLUSIONS AND FUTURE DIRECTIONS
Our data suggests that prolonged resveratrol supplementation can potentially induce molecular
changes that may prove beneficial for combating physiological decline with increasing age and
bodyweight. Although we did not observe any significant behavioral changes, it is possible that a
higher dose is needed to effect these changes. The dose used in our study was based on 36 and did
not account for the increased bodyweight introduced as a confounding factor in our experiments.
Future studies will be conducted with a dose corrected for increased bodyweight. It will also be
interesting to compare and contrast our model to current obesity models that use a high-fat diet in
terms of molecular and behavioral changes. An exhaustive analysis of fat content and type
(brown vs. white), cholesterol levels, changes in cardiovascular, renal and hepatic systems will
prove instrumental in further characterization of our model. Finally, addition of an exercise
component to the study will be allow us to gauge combined effects of natural antioxidant
supplementation and physical activity on overall health and function with advancing age.
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CHAPTER TWO
Neuroprotective effects of the resveratrol analog piceid in dopaminergic SH-SY5Y cells
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INTRODUCTION AND RATIONALE
Several genetic, molecular, and cellular mechanisms leading to oxidative stress, mitochondrial
dysfunction, and apoptosis have been shown to contribute to dopamine (DA) neuronal
dysfunction and its loss with normal aging and neurodegenerative diseases like Parkinson’s
disease (PD)

228-234

. However, the underlying mechanisms remain elusive. Till to date no drug

therapy is available to halt the progressive loss of DA neurons that occurs in the aging brain.
In humans, basal oxidative stress and oxidative damage are higher in the substantia nigra pars
compacta (SNpc), a region rich in dopaminergic neurons, as compared to other areas of the brain
235

. It is thought that this may be due, in part, to the autoxidation of DA leading to the formation

of reactive oxygen species (ROS) and reactive nitrogen species (RNS), dopamine-quinone
species, superoxide radicals, and hydrogen peroxide

236-238

. Studies have also shown that toxin239-242

induced oxidative stress causes nigral cell degeneration

. Moreover, an increase in

oxidative stress, as indicated by increases in lipid peroxidation, protein and DNA oxidation has
been observed in the aged brain and PD patients

243-248

.

Therefore, devising therapeutic

interventions that can lead to the reduction in oxidative stress in DA regions are of extreme
importance.
Resveratrol (trans-3, 5, 4-trihydroxystilbene), a polyphenolic compound that is present in many
dietary sources, such as grapes, red wine, and peanuts possess antioxidant, anti-inflammatory,
and anti-apoptotic properties

242, 249-251

. Resveratrol has been shown to protect DA neurons

against several toxins, including 1-methyl-4-phenyl pyridinium (MPP+), 6-hydroxydopamine (6OHDA), and lipopolysaccharide (LPS)

240-242, 252

. However, the oral absorption of resveratrol is

extremely low due to rapid and extensive metabolism resulting in only trace amounts of
unchanged resveratrol in the systemic circulation
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253-255

, limiting its therapeutic potential. It is

therefore necessary to explore analogs of resveratrol that show similar protective effects but
circumvent rapid biotransformation.
Piceid (3, 5, 4’-trihydroxystilbene-3-O-β-D-glucopyranoside), or polydatin, is a stilbenoid
glucoside and a resveratrol precursor (glycoside form of resveratrol) found in grapes and red
wines

256

. Piceid retains the biological properties of resveratrol but is less susceptible to

enzymatic oxidation. Similar to resveratrol, piceid has been shown to have antioxidant
anti-inflammatory properties

258

257

and

. Previous studies have shown that oral administration of piceid

results in high levels of resveratrol in vivo and increases the amount of trans-resveratrol available
from the diet

259

. Further, piceid has been shown to exhibit higher scavenging activity against

hydroxyl radicals than resveratrol in vitro

260

. However, it is not known whether piceid has the

ability to defend dopaminergic cells against oxidative stress.
To understand the underlying mechanism of neuroprotection, it is important to examine cellsignaling pathways that play a role in neuronal survival. Extracellular signal-regulated kinases
ERK1/2 and ERK5 are two prime members of the mitogen-activated protein kinase (MAPK)
family of proteins and are considered important for the neuronal survival against oxidative stress
261-263

. ERK1/2 and ERK5 are known to increase the survival of DA neurons under basal

conditions

264

and following neurotoxin-induced oxidative stress

263, 265

. Further, modulation of

these signaling pathways is observed in dopaminergic brain regions during postnataldevelopment and aging

265-266

. This study examined the effects of piceid on DA-induced cell

death and ERK1/2 and ERK5 signaling pathways in human dopaminergic-like SH-SY5Y cells.
To the best of our knowledge, this is probably the first report indicating a possible regulatory
role for piceid on ERK activity. Our data suggest that piceid protects SH-SY5Y cells against
DA-induced toxicity and the protective effect of piceid is mediated via ERK activation. Piceid
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pretreatment also reduced caspase-3/7 activity and increased the expression of Bcl-2, suggesting
that piceid inhibits apoptosis induced by DA.
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MATERIALS AND METHODS
Cell Culture
Undifferentiated, low-passage (P3-P10) human dopaminergic neuroblastoma cell line, SHSY5Y, was cultured in Dulbecco's Modified Eagle's medium (DMEM, Cat. No. 11965-084, Life
Technologies) supplemented with 10% (v/v) fetal bovine serum (Cat. No. S11550, Atlanta
Biologicals, Atlanta, GA), 0.05 units/ml penicillin, and 0.05 mg/ml streptomycin (Cat. No.
P0781, Sigma-Aldrich, St. Louis, MO) and maintained at 37ºC in a humidified 5% CO2
atmosphere. Cells were plated at a density of 6.0 x 106 cells per 35mm plate or 1.5 x 104 cells per
well in 96 well plates 48 hr before treatment. Cell culture reagents, unless otherwise noted, were
purchased from Sigma-Aldrich.
DA treatment
DA (Cat. No. H850, Sigma Aldrich) was dissolved in sterile water to an initial concentration of
100mM. The DA solution was further diluted with sterile water to the required concentration.
Concentration-dependent toxicity of DA was determined by treating SH-SY5Y cells with 50,
100, 150, and 200µM for 12 hr. The 150µM concentration of DA which caused ~50% loss of
cell viability at 12 hr, was used for subsequent experiments with piceid and/or kinase inhibitor
pretreatment.
Piceid treatment
Piceid was purchased from TCI America (CAS Number: 27208-80-6). A stock solution of piceid
was dissolved in Dimethyl sulfoxide (DMSO, Sigma Aldrich). For each treatment, a fresh
dilution of piceid was made in serum-free media. Several pilot experiments were conducted to
determine the optimum dose of piceid that could protect SH-SY5Y cells against DA-mediated
toxicity. In our preliminary experiments, we found that a dose lower than 10μM and higher than
30μM was not able to significantly attenuate dopamine-induced toxicity in SH-SY5Y cells
71

(Figure 21B). Therefore, cells were pretreated with 10, 20, and 30µM dose of piceid for 1 hr
prior to exposure to DA. After several experiments, 30µM piceid was used for further
experiments, as this dose was found to be most effective in protecting SH-SY5Y cells against
DA-mediated toxicity. DMSO was used as a vehicle control.
U0126 or XMD8-92 inhibitor treatments
To block phosphorylation of ERK1/2 or ERK5, SH-SY5Y cells were treated with U0126 (10
µM; Cat. No. 662005, Calbiochem, San Diego, CA) or XMD8-92 (10 µM, Cat. No. 4132 Tocris
bioscience, Bristol, UK), respectively, 1 hr prior to piceid (30μM) treatment for different time
points. DMSO was used as a vehicle control.
Cell viability assays
Cell viability was determined using two different viability assays i) CellTiter-Glo® Luminescent
Assay (Cat. No. G7570, Promega Inc., Madison, WI) and ii) dead cell protease assay (Cat. No.
G7570, Promega Inc., Madison, WI). For both assays, cell viability was measured in a black,
clear-bottomed 96-well plate (Cat. No. 3603, Corning Inc.) according to manufacturer’s
instructions. Luminescence was measured on a microplate reader (Victor3 1420 multilabel
counter, PerkinElmer, MA).
Caspase-Glo® 3/7 Activity Assay
The activity of caspase-3/7 was detected in 96-well (Cat. No. 3603, Black plate with clear
bottom, Corning Incorporated) format using the Caspase-Glo® 3/7 assay (Cat. No. G8091,
Promega Inc.) per the manufacturer’s instructions. Briefly, 100µL of the Caspase-Glo 3/7
reagent were added to each well containing 100µL of media and cells. The contents of wells
were gently mixed using a plate shaker at 300-500 rpm for 30 sec. The plate was then incubated
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at room temperature for 1 hr. Luminescence was measured on a microplate reader (Victor3 1420
multilabel counter, PerkinElmer, MA).
Cell lysis collection for western blot analysis
Cell lysates were collected using lysis buffer containing 20mM Tris, pH 6.8, 137mM NaCl,
25mM β-glycerophosphate, pH 7.14, 2mM NaPPi, 2mM EDTA, 1mM Na3VO4, 1% Triton X100, 10% glycerol, 5μg/ml leupeptin, 5μg/ml aprotinin, 2mM benzamidine, 0.5mM DTT, and
1mM PMSF. Cell lysates were centrifuged at 11,000 rpm for 30 min at 4ºC and the supernatant
was collected and stored at -80ºC until used for western blot analysis.
Western blotting
Total protein content was assessed by Bradford Bio-Rad protein assay (Cat. No. 500-0006, BioRad, Hercules, CA) and 30μg of protein was detected using 8% SDS-PAGE for phosphorylated
and total ERK1/2 and ERK5 proteins, and 12% SDS-PAGE for Bcl-2 protein. After running the
samples, gels were transferred to a nitrocellulose membrane (Cat. No. 926-31092, Licor
Biosciences, Lincoln, NE). The membranes were washed for 5 min with 1X PBS and blocked for
1 hr in a Casein Blocking Buffer (CBB, Cat. No. 927-40200, Licor Biosciences) at room
temperature. Membranes were then incubated overnight at 4ºC in primary antibody in CBB with
0.2% Tween-20. Antibodies included rabbit anti-phospho-ERK1/2 (Dilution–1:1000, Cat. No.
9101, Cell Signaling, Beverly, MA), mouse anti-total ERK1/2 (Dilution–1:2000, Cat. No. 9107,
Cell Signaling), rabbit anti-total ERK5 (Dilution–1:1,000, Cat. No. 3372, Cell Signaling), and
rabbit anti-total Bcl-2 (Dilution–1:1000, Cat. No. 2876S, Cell Signaling). Mouse anti-α-Tubulin
(Dilution-1:10,000, Cat. No. T5168, Sigma–Aldrich) was used as a loading control. After
incubation with primary antibody, blots were washed in 1X PBS solution with 0.2% Tween-20
(1X PBS-T) and incubated with goat anti-rabbit (Dilution–1:20,000, Cat. No. 926-68021, Licor
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Biosciences) and goat anti-mouse (Dilution–1:20,000, Cat. No. 926-32210, Licor Biosciences)
secondary antibodies for 1hr at room temperature. After washing the membranes with 1X PBST, the protein bands were visualized on an Odyssey Infrared Imager and quantified with Odyssey
software (Licor Biosciences).
Statistical analysis
GraphPad Prism 5 Software (San Diego, CA) was used for statistical analysis. Data are
expressed as mean ± SEM. For viability studies, statistical significance was determined by oneway ANOVA followed by the Dunnett post hoc test. Statistical significance was defined at p<
0.05
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RESULTS
Piceid attenuated DA-induced cell death in SH-SY5Y cells
Chemical structures of resveratrol and its analog piceid are shown (Figure 20). SH-SY5Y cells
were treated with increasing DA concentrations (100-250µM) for 12 hr to induce toxicity. A
dose-dependent loss in cell viability, as measured by ATP levels, was noted following DA
treatment with a 50% loss of cell viability following treatment with 150µM DA (Figure 21A,
21B, 21C). Similarly, an increase in dead-cell protease activity was observed following 150µM
DA treatment (Figure 21D) indicating cell death. Pretreatment with piceid (10-30μM)
significantly decreased the DA-induced loss of cell viability as measured by significant increase
in ATP levels (Figure 21B, 21C) and reduction in dead-cell protease activity (Figure 21D). As
30μM piceid showed the maximum protection, we chose this dose for subsequent experiments.
These data undoubtedly suggested that piceid attenuates DA-induced cell death in SH-SY5Y
cells.
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Figure 20. Chemical structures of piceid and resveratrol
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Figure 21. Piceid (RV8) protects against DA-induced toxicity in SH-SY5Y cells
(A) Concentration-dependent loss of cell viability in SH-SY5Y cells. Cells were treated with 0250μM of DA for 12 hr. For (B) (C) and (D) SH-SY5Y cells were pretreated with indicated
concentrations of RV8 (1 hr) with or without DA. Cell Titer Glo (B,C) and Dead-protease
fluorescence (D) were used to measure ATP levels and dead-cell protease levels, respectively.
Each experiment was performed 3 independent times and data is presented as mean ± standard
error of mean. Statistical analysis was applied using one-way ANOVA followed by Dunnett's
post hoc test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. # indicates compared to vehicle
while * and n.s. indicates compared to 150μM DA.
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Piceid activates pro-survival proteins ERK1/2 and ERK5 in SH-SY5Y cells
SH-SY5Y cells were treated with 30μM piceid at different time points (5, 10, 15, 30, 60, 120
min, 12 hr and 24 hr) to study possible regulatory role for piceid on ERK activity. Treatment of
the cells with piceid resulted into ERK1/2 (Figure 22A, 22C) and ERK5 (Figure 22B, 22C)
phosphorylation, indicative of activation of these pathways. Significant increase in activation of
ERK1/2 was observed at 5 min and ERK5 at 2 hr. It is important to note that for all the treatment
points, the activation for ERK1/2 and ERK5 was higher than the control, except ERK5 activation
is back to basal similar to control.
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Figure 22. Piceid (RV8) causes activation (phosphorylation) of ERK1/2 and ERK5 in SHSY5Y cells
Quantification of the immunoblots for ERK1/2 (A) and ERK5 (B) using Licor Odyssey software.
The values are calculated using the integrated intensity. Protein expression was standardized to
basal total protein. Data are expressed as mean ± standard error of the mean. *p<.0.05 compared
to the 0 time point. (C) Representative immunoblots of total and phosphorylated ERK1/2 and
total and phosphorylated ERK5 in SH-SY5Y cells indicating RV8 activates (phosphorylates)
ERK1/2 and ERK5 in a time-dependent manner. U0126 (10µM) and XMD8-92 (10µM) were
used as inhibitors of phosphorylated ERK1/2 and phosphorylated ERK5 respectively.
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Inhibition of the ERK1/2 and ERK5 pathways attenuates piceid-mediated neuroprotection
in SH-SY5Y cells
To determine if activation of ERK1/2 and/or ERK5 was involved in piceid-mediated
neuroprotection, we used pharmacological inhibitors of MEK1/2, kinases upstream of ERK1/2,
and ERK5. SH-SY5Y cells were pretreated with 10μM of U0126, the MEK1/2 inhibitor, or
XMD8-92, the ERK5 inhibitor, for 1 hr. Cells were then treated with piceid for 1hr following
which they were exposed to 150μM of DA for 12 hr. The piceid-mediated protection against
DA-induced cell loss was attenuated following inhibition of ERK1/2 and ERK5 activation
(Figure 23A, 23B). These data suggest that ERK1/2 and ERK5 play a role in piceid-mediated
neuroprotection of SH-SY5Y cells.
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Figure 23.Inhibition of ERK1/2 and ERK5 activation independently in SH-SY5Y cells
attenuates RV8-mediated neuroprotection
SH-SY5Y cells were pretreated with U0126 (10µM) or XMD8-92 (10µM) followed by RV8
(30µM) for 1 hr with or without DA. Cell Titer Glo (A) and Dead-protease fluorescence (B)
were used to measure ATP levels and dead-cell protease levels respectively. Each experiment
was performed 3 independent times and data is presented as mean ± standard error of mean.
Statistical analysis was applied using one-way ANOVA followed by Dunnett's post hoc test.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. # indicates compared to vehicle while * and n.s.
indicates compared to 150μM DA.
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Piceid attenuates DA-induced oxidative stress in SH-SY5Y cells
High concentrations of DA cause toxicity, partly via induction of oxidative stress. In our study,
dopamine at 150μM caused a significant increase in the levels of malondialdehyde (MDA), a
reactive carbonyl compound derived from lipid peroxides. Piceid (30μM) significantly attenuated
this increase in MDA levels (Figure 24). These data indicate that reduction of DA-induced
oxidative stress is one of the mechanisms responsible for piceid-mediated protection in SHSY5Y cells.
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Figure 24. Piceid attenuated oxidative stress associated with DA- induced toxicity
SH-SY5Y cells were exposed to DA (150μM) treatment in the presence or absence of RV8
(30µM). Each experiment was performed 3 independent times and data is presented as mean ±
standard error of mean. Statistical analysis was applied using one-way ANOVA followed by
Dunnett's post hoc test. *p<0.05. # indicates compared to vehicle while * indicates compared to
150μM DA.
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Piceid attenuates DA-induced caspase-3/7 activity and increases levels of the anti-apoptotic
protein Bcl-2 in SH-SY5Y cells
The increase in oxidative stress has been known to modulate expression levels of Bcl-2 family
members (anti-apoptotic and pro-apoptotic proteins), resulting in activation of caspase pathway,
thereby, apoptotic cellular death. We tested the levels of expression of Bcl-2, an anti-apoptotic
protein, following DA exposure. Treatment with DA caused a decrease in Bcl-2 expression,
which was very effectively reversed by piceid pretreatment (Figure 25A, 25B). Caspases play
key effector roles in apoptotic cell death. Activation of caspase-3/7 results in activation of DNA
fragmentation factor, which further activates endonucleases to cleave DNA and results in
apoptosis. To further investigate the mechanism of neuroprotection by piceid, we tested caspase3/7 activity in SH-SY5Y cells that were pretreated with piceid (10-30μM) and then exposed to
DA (150μM). Piceid pretreatment inhibited the increase in caspase-3/7 levels in following DA
treatment (Figure 25C). These results indicate that piceid exerts its neuroprotective effects, in
part, via inhibition of apoptotic cell death through up regulation of Bcl-2 protein and reduction in
caspase-3/7 activity. A schematic of the proposed mechanism has been depicted in Figure 26.
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Figure 25. Piceid (RV8) pretreatment attenuates DA-mediated apoptosis in SH-SY5Y cells
(A) Representative immunoblot of total Bcl-2 in SH-SY5Y cells indicating RV8 inhibited DAinduced loss of Bcl-2 expression (B) Quantification of Bcl-2 immunoblots using Licor Odyssey
software. The values are calculated using the integrated intensity. Protein expression was
standardized to α-tubulin. Data are expressed as mean ± standard error of the mean. *p<.0.05
compared to the 0 time point. (C) SH-SY5Y cells were pretreated with indicated concentrations
of RV8 (1 hr) with or without DA. Caspase 3/7 activity was used to measure apoptosis. Each
experiment was performed 3 independent timesand data is presented as mean ± standard error of
mean. Statistical analysis was applied using one-way ANOVA followed by Dunnett's post hoc
test. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. # indicates compared to vehicle while *
indicates compared to 150μM DA.
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Figure 26. Schematic of proposed neuroprotective mechanism of piceid
The flowchart shows potential mechanistic intervention of piceid in the reduction of DA-induced
oxidative stress and cellular death. Our study indicates piceid to reduce DA-induced oxidative
stress mediated SH-SY5Y cellular death by 1) activation of ERK1/2 and ERK5 cellular signaling
pathway and 2) reduction in caspase-3/7 activation thereby reducing apoptosis.
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DISCUSSION
In this study, we have examined the cytoprotective effect of piceid in the SH-SY5Y
dopaminergic neuronal cell line against DA-induced toxicity. Another important mechanistic
goal was to elucidate the underlying signaling mechanisms that could be possibly be involved in
piceid-mediated neuroprotection. Our data show that DA induced dose-dependent cytotoxicity in
SH-SY5Y cells, and DA-induced cell death was considerably attenuated by piceid (10-30μM) as
measured by an increase in ATP levels and reduction in dead-cell protease levels following
piceid treatment prior to DA exposure. This is in accordance with the piceid-mediated protection
seen in cisplatin-induced oxidative stress in rats

267

and resveratrol-mediated protection against

DA-induced cytotoxicity 238.
Extracellular signal-regulated kinases (ERK), ERK1/2 and ERK5, are members of the MAPK
family of proteins. ERK1/2 and/or ERK5 have been shown to promote the basal survival of DA
neurons and inhibit neurotoxin induced oxidative stress in SH-SY5Y cells

263, 265

. In order to

determine whether activation of ERK1/2 and/or ERK5 is involved in piceid-mediated protection
against DA-induced toxicity, SH-SY5Y cells were treated with piceid and ERK1/2 and ERK5
activation were examined. Treatment with piceid resulted in activation of ERK1/2 and ERK5.
This study, to our knowledge is the first study, which shows piceid-mediated activation of
ERK5. However, our data slightly differ from other reports of ERK1/2 inhibition by piceid
although most of those findings were observed in non-neuronal cell line models
differences could be due to the use of different cell types

65, 180, 270-271

268-269

. These

. In our study, we also

observed that piceid activates ERK1/2 and ERK5 at different time points. Differential expression
of ERK1/2 and ERK5 has been observed with different stimuli (Cavanaugh et al., 2001);
including early development where activation of these kinases is regulated differently (Parmar et
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al., 2015). To examine the role of ERK activation in piceid-mediated protection, we inhibited the
ERK1/2 and ERK5 pathways independently using U0126 and XMD8-92, respectively. Piceidmediated protection was attenuated following ERK1/2 and ERK5 inhibition, suggesting that both
pathways may play a role in the neuroprotection afforded by piceid. Our findings are consistent
with the earlier observations in SH-SY5Y cells that suggest the ERK1/2 and ERK5 activation
protects against oxidative stress in SH-SY5Y cells 263, 272.
Natural antioxidants have been shown to up regulate the expression of anti-apoptotic proteins
(e.g. Bcl-2, Bcl-XL) or reduce the expression pro-apoptotic proteins (e.g. Bad), both of which
result in decreases in cytochrome c release and caspase activity

273

results in DNA fragmentation, cleavage and eventually apoptosis

. Activation of caspase-3/7

274

. Bcl-2, a member of the

Bcl-2 family, plays a crucial role in maintaining mitochondrial membrane potential and has been
shown to regulate caspase activation

275

. In our study, DA treatment decreased Bcl-2 protein

levels and increased caspase-3/7 activity in SH-SY5Y cells. These data suggest that the loss of
viability noted following DA treatment of SH-SY5Y cells may be due to an increase in
apoptosis. Piceid pretreatment inhibited the DA-mediated loss of Bcl-2 protein expression and
activation of caspase-3/7 activity. These cytoprotective properties could be associated with the
ability of piceid to minimize the loss of plasma membrane potential and mitochondrial
membrane potential and maintained cellular homeostasis
piceid pretreatment decreases DA-mediated apoptosis.
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276

. Together these data suggest that

CONCLUSION AND FUTURE DIRECTIONS
In conclusion, we have shown that piceid can protect against DA-induced apoptotic cell death of
human dopaminergic neuroblastoma SH-SY5Y cells through activation of the MAPKs ERK1/2
or ERK5 and inhibition of caspase-3/7 activity. Further studies will test piceid in primary
neuronal cultures and animal models of aging. A long-term animal study of piceid, testing
bioavailability and other biopharmaceutical characters including pharmacokinetics and
pharmacodynamics, will provide a better understanding of the metabolism of this compound in
vivo and its potential in aging, obesity and neurodegenerative disorders.
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